metformin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 387.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.64 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 28, 2006 EMA CHEPLAPHARM Arzneimittel GmbH
March 3, 1995 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 14236.24 9.98 5963 329295 29383 55927426
Acute kidney injury 3854.19 9.98 5861 329397 234902 55721907
Hypoglycaemia 3197.91 9.98 2653 332605 53162 55903647
Metabolic acidosis 2366.60 9.98 1947 333311 38507 55918302
Diabetic ketoacidosis 2198.16 9.98 1381 333877 17490 55939319
Blood glucose increased 2051.84 9.98 2381 332877 72770 55884039
Ketoacidosis 1040.33 9.98 501 334757 3574 55953235
Glycosylated haemoglobin increased 1026.66 9.98 705 334553 10460 55946349
Diabetes mellitus inadequate control 1013.43 9.98 764 334494 13216 55943593
Hyperkalaemia 934.73 9.98 1325 333933 49540 55907269
Rheumatoid arthritis 912.12 9.98 578 334680 382026 55574783
Euglycaemic diabetic ketoacidosis 868.78 9.98 410 334848 2779 55954030
Hyperglycaemia 853.97 9.98 1096 334162 37185 55919624
Systemic lupus erythematosus 843.91 9.98 59 335199 180019 55776790
Pemphigus 768.24 9.98 41 335217 157171 55799638
Glossodynia 683.34 9.98 61 335197 152397 55804412
Hand deformity 641.98 9.98 40 335218 134452 55822357
Synovitis 573.71 9.98 129 335129 161176 55795633
Drug ineffective 553.27 9.98 3219 332039 915770 55041039
Hypoglycaemic coma 550.23 9.98 273 334985 2094 55954715
Contraindicated product administered 521.86 9.98 228 335030 186058 55770751
Arthropathy 519.96 9.98 272 334986 200003 55756806
Drug intolerance 512.63 9.98 493 334765 264325 55692484
Pericarditis 497.82 9.98 40 335218 108883 55847926
Shock 468.67 9.98 612 334646 21116 55935693
Diabetes mellitus 455.62 9.98 985 334273 51750 55905059
Infusion related reaction 452.85 9.98 349 334909 208582 55748227
Treatment failure 442.83 9.98 231 335027 170161 55786648
Pancreatitis acute 437.19 9.98 638 334620 24486 55932323
Blood glucose decreased 429.49 9.98 549 334709 18538 55938271
Pancreatitis 409.01 9.98 859 334399 44221 55912588
Wound 406.23 9.98 159 335099 138645 55818164
Joint swelling 396.72 9.98 699 334559 289101 55667708
Alopecia 396.17 9.98 714 334544 292744 55664065
Anuria 384.73 9.98 410 334848 11350 55945459
Hyperlactacidaemia 377.67 9.98 219 335039 2369 55954440
Renal failure 376.12 9.98 1477 333781 109023 55847786
Duodenal ulcer perforation 375.96 9.98 6 335252 68336 55888473
Diarrhoea 374.28 9.98 5598 329660 632909 55323900
Swelling 368.95 9.98 535 334723 239236 55717573
Diabetic metabolic decompensation 355.27 9.98 177 335081 1371 55955438
Blood glucose abnormal 343.20 9.98 309 334949 6919 55949890
Rheumatoid factor positive 334.11 9.98 19 335239 69041 55887768
Discomfort 333.06 9.98 217 335041 141544 55815265
Pemphigoid 322.39 9.98 281 334977 6019 55950790
Therapeutic product effect decreased 321.21 9.98 321 334937 169131 55787678
Helicobacter infection 318.40 9.98 33 335225 73235 55883574
Vomiting 317.46 9.98 4434 330824 493794 55463015
Hypersensitivity 297.21 9.98 681 334577 255727 55701082
Dehydration 296.12 9.98 1786 333472 157039 55799770
Rash 294.92 9.98 1727 333531 491320 55465489
Drug level increased 268.75 9.98 460 334798 20265 55936544
Muscle injury 264.99 9.98 11 335247 52489 55904320
Pain 259.45 9.98 2614 332644 660570 55296239
Folliculitis 254.49 9.98 19 335239 54960 55901849
Haemodialysis 250.58 9.98 282 334976 8309 55948500
Hypothermia 245.54 9.98 336 334922 12134 55944675
Abdominal discomfort 243.87 9.98 841 334417 276433 55680376
Infection 236.55 9.98 526 334732 199680 55757129
Product use issue 231.28 9.98 475 334783 185566 55771243
Irritable bowel syndrome 231.01 9.98 61 335197 68397 55888412
Sleep disorder due to general medical condition, insomnia type 225.95 9.98 7 335251 43331 55913478
Toxicity to various agents 225.55 9.98 2184 333074 222380 55734429
Off label use 218.98 9.98 2188 333070 553992 55402817
Musculoskeletal stiffness 217.08 9.98 372 334886 155635 55801174
Drug interaction 197.50 9.98 2013 333245 207742 55749067
Blood lactic acid increased 194.08 9.98 209 335049 5855 55950954
Vitamin B12 deficiency 189.50 9.98 178 335080 4215 55952594
Impaired healing 189.29 9.98 144 335114 86697 55870112
Rhabdomyolysis 188.59 9.98 602 334656 40056 55916753
Continuous haemodiafiltration 185.33 9.98 99 335159 900 55955909
Stomatitis 179.35 9.98 276 334982 120534 55836275
Weight decreased 179.25 9.98 2206 333052 238508 55718301
Maternal exposure during pregnancy 168.49 9.98 572 334686 188981 55767828
Pancreatic carcinoma 167.18 9.98 211 335047 7030 55949779
Hepatic enzyme increased 167.17 9.98 496 334762 170888 55785921
Blood glucose fluctuation 162.63 9.98 162 335096 4133 55952676
Arthralgia 156.45 9.98 2078 333180 499591 55457218
Pyrexia 155.67 9.98 1669 333589 417104 55539705
Intentional overdose 141.07 9.98 788 334470 67329 55889480
Rheumatic fever 133.29 9.98 10 335248 28817 55927992
Febrile neutropenia 133.17 9.98 267 334991 105278 55851531
Ill-defined disorder 133.05 9.98 127 335131 68416 55888393
Neurologic neglect syndrome 130.90 9.98 107 335151 2091 55954718
Hypomagnesaemia 130.54 9.98 386 334872 24629 55932180
Nausea 127.57 9.98 5662 329596 758516 55198293
Sinusitis 127.51 9.98 674 334584 196907 55759902
Drug hypersensitivity 126.95 9.98 1039 334219 274166 55682643
Carotid artery thrombosis 126.89 9.98 106 335152 2138 55954671
Blister 124.50 9.98 291 334967 108596 55848213
Acidosis 124.37 9.98 224 335034 10277 55946532
Completed suicide 120.42 9.98 1273 333985 132560 55824249
Overdose 119.52 9.98 1056 334202 104774 55852035
Fatigue 118.25 9.98 3689 331569 784863 55171946
C-reactive protein abnormal 118.24 9.98 36 335222 36773 55920036
Personality disorder 116.68 9.98 149 335109 5024 55951785
Renal impairment 113.12 9.98 846 334412 79867 55876942
Hemiplegia 112.20 9.98 189 335069 8215 55948594
Blood creatinine increased 112.09 9.98 840 334418 79351 55877458
Tachypnoea 110.79 9.98 268 334990 15162 55941647
Adjustment disorder 109.67 9.98 99 335159 2224 55954585
Contusion 108.40 9.98 396 334862 128034 55828775
Polyuria 107.78 9.98 175 335083 7376 55949433
Blood bicarbonate decreased 106.61 9.98 105 335153 2641 55954168
Hip arthroplasty 103.77 9.98 50 335208 38573 55918236
Myocardial infarction 101.43 9.98 920 334338 91950 55864859
Ketosis 100.33 9.98 55 335203 529 55956280
Insulin resistance 94.67 9.98 58 335200 699 55956110
Injection site nodule 91.69 9.98 109 335149 3410 55953399
Cardiac arrest 90.69 9.98 848 334410 85466 55871343
Product residue present 88.27 9.98 111 335147 3684 55953125
Neutropenia 85.85 9.98 570 334688 157597 55799212
Urine ketone body present 83.32 9.98 86 335172 2291 55954518
MELAS syndrome 83.25 9.98 31 335227 103 55956706
Postprandial hypoglycaemia 82.24 9.98 26 335232 43 55956766
Mobility decreased 80.41 9.98 310 334948 98681 55858128
Acetonaemia 80.31 9.98 29 335229 86 55956723
Hypotension 79.65 9.98 2004 333254 248504 55708305
Diabetic neuropathy 78.37 9.98 104 335154 3644 55953165
Anion gap increased 76.99 9.98 68 335190 1483 55955326
Ketonuria 74.93 9.98 44 335214 488 55956321
Hepatic steatosis 74.66 9.98 332 334926 25882 55930927
Microalbuminuria 73.72 9.98 39 335219 347 55956462
Hypoglycaemic encephalopathy 72.04 9.98 35 335223 255 55956554
Therapeutic product effect incomplete 71.56 9.98 356 334902 105675 55851134
Suicide attempt 70.99 9.98 588 334670 57248 55899561
Peripheral swelling 70.82 9.98 978 334280 233748 55723061
Vasoplegia syndrome 69.61 9.98 60 335198 1265 55955544
Angioedema 68.30 9.98 452 334806 41001 55915808
Drug level above therapeutic 67.64 9.98 105 335153 4257 55952552
Bradycardia 66.35 9.98 654 334604 66850 55889959
Diabetic retinopathy 65.88 9.98 74 335184 2175 55954634
Circulatory collapse 65.03 9.98 271 334987 20532 55936277
Anaemia vitamin B12 deficiency 64.98 9.98 35 335223 324 55956485
Coma acidotic 64.59 9.98 25 335233 95 55956714
Affect lability 64.45 9.98 168 335090 9957 55946852
Nasopharyngitis 64.40 9.98 927 334331 220032 55736777
Therapy non-responder 63.86 9.98 172 335086 61183 55895626
Knee arthroplasty 63.85 9.98 103 335155 44156 55912653
Motor dysfunction 63.39 9.98 160 335098 9297 55947512
Cytomegalovirus infection 61.74 9.98 19 335239 19277 55937532
Glomerular filtration rate decreased 61.26 9.98 187 335071 12142 55944667
Glycosylated haemoglobin decreased 60.37 9.98 38 335220 482 55956327
Atrioventricular block 59.84 9.98 129 335129 6758 55950051
Bone erosion 59.55 9.98 9 335249 14965 55941844
Renal tubular necrosis 59.29 9.98 170 335088 10658 55946151
Haemodynamic instability 58.02 9.98 143 335115 8186 55948623
Oliguria 57.84 9.98 144 335114 8296 55948513
Psoriasis 57.80 9.98 823 334435 91869 55864940
Cholelithiasis 57.75 9.98 418 334840 39046 55917763
Hyponatraemia 57.49 9.98 891 334367 101248 55855561
Product prescribing error 57.47 9.98 282 334976 22904 55933905
Tubulointerstitial nephritis 56.80 9.98 223 335035 16442 55940367
Psoriatic arthropathy 56.78 9.98 237 335021 73771 55883038
Eating disorder 55.98 9.98 226 335032 16879 55939930
Blood potassium increased 55.64 9.98 227 335031 17034 55939775
Product odour abnormal 55.35 9.98 49 335209 1072 55955737
Condition aggravated 54.68 9.98 1600 333658 343298 55613511
Blood ketone body increased 54.53 9.98 29 335229 261 55956548
Myopathy 53.68 9.98 154 335104 9658 55947151
Migraine 53.22 9.98 301 334957 86496 55870313
Polydipsia 53.16 9.98 80 335178 3155 55953654
Dysarthria 52.83 9.98 410 334848 39140 55917669
Sensory loss 52.58 9.98 144 335114 8791 55948018
Choreoathetosis 52.09 9.98 34 335224 461 55956348
Unresponsive to stimuli 51.70 9.98 345 334913 31380 55925429
Arthritis 51.60 9.98 365 334893 99487 55857322
Abdominal pain 50.65 9.98 1952 333306 256853 55699956
Inflammation 50.06 9.98 226 335032 68845 55887964
Amylase increased 50.03 9.98 108 335150 5663 55951146
Foot deformity 50.01 9.98 41 335217 23784 55933025
Loss of personal independence in daily activities 49.99 9.98 282 334976 81087 55875722
Anaemia megaloblastic 49.87 9.98 30 335228 349 55956460
Hypovolaemic shock 49.41 9.98 103 335155 5270 55951539
Immune-mediated myositis 48.94 9.98 47 335211 1145 55955664
Tenosynovitis 48.40 9.98 8 335250 12453 55944356
Macroangiopathy 48.34 9.98 20 335238 94 55956715
Anhidrosis 48.17 9.98 20 335238 95 55956714
Dialysis 48.06 9.98 147 335111 9555 55947254
Cerebrovascular accident 47.04 9.98 842 334416 98428 55858381
Toothache 46.87 9.98 221 335037 17659 55939150
Death 46.85 9.98 1614 333644 339812 55616997
Malaise 46.73 9.98 2657 332601 365203 55591606
Glycosylated haemoglobin abnormal 46.56 9.98 20 335238 105 55956704
Cerebral venous thrombosis 46.17 9.98 57 335201 1856 55954953
Liver injury 46.09 9.98 114 335144 41734 55915075
Acute coronary syndrome 45.61 9.98 145 335113 9623 55947186
C-reactive protein increased 45.51 9.98 278 334980 78406 55878403
Diabetic nephropathy 45.40 9.98 48 335210 1316 55955493
Lipase increased 45.37 9.98 137 335121 8842 55947967
Exposure during pregnancy 45.13 9.98 1097 334161 135245 55821564
Multiple organ dysfunction syndrome 44.65 9.98 496 334762 52274 55904535
Latent autoimmune diabetes in adults 44.26 9.98 13 335245 14 55956795
Intentional product use issue 43.87 9.98 381 334877 99352 55857457
Fibromyalgia 43.80 9.98 194 335064 59409 55897400
Blood creatine phosphokinase increased 43.78 9.98 301 334957 27651 55929158
Drug resistance 43.55 9.98 35 335223 20507 55936302
Product use in unapproved indication 43.41 9.98 584 334674 140238 55816571
Hemiparesis 43.40 9.98 247 335011 21243 55935566
Lower respiratory tract infection 43.08 9.98 456 334802 114338 55842471
Prerenal failure 43.05 9.98 50 335208 1525 55955284
Blindness transient 43.01 9.98 76 335182 3434 55953375
Hyperglycaemic hyperosmolar nonketotic syndrome 42.44 9.98 34 335224 645 55956164
White blood cell count decreased 42.36 9.98 513 334745 125477 55831332
Urinary tract discomfort 42.18 9.98 26 335232 317 55956492
Pancreatic carcinoma metastatic 42.16 9.98 59 335199 2176 55954633
Sopor 41.94 9.98 240 335018 20682 55936127
Electrocardiogram T wave peaked 41.75 9.98 22 335236 194 55956615
Blood cholesterol increased 41.68 9.98 257 335001 72322 55884487
Thrombocytopenia 41.61 9.98 566 334692 135658 55821151
Adverse event 41.45 9.98 179 335079 55197 55901612
Pneumonia 41.00 9.98 1994 333264 405104 55551705
Cleft lip 40.22 9.98 18 335240 106 55956703
Device expulsion 40.14 9.98 75 335183 30374 55926435
Gastroenteritis 40.10 9.98 266 334992 24146 55932663
Plasma cell myeloma 39.87 9.98 143 335115 46503 55910306
Haemophagocytic lymphohistiocytosis 39.84 9.98 5 335253 9567 55947242
Leukopenia 39.80 9.98 253 335005 70687 55886122
Pneumocystis jirovecii pneumonia 39.68 9.98 22 335236 15679 55941130
Transplant rejection 39.44 9.98 6 335252 9928 55946881
Pharyngitis 39.38 9.98 216 335042 18322 55938487
Myelosuppression 39.24 9.98 28 335230 17427 55939382
Seizure 38.88 9.98 518 334740 124601 55832208
Coronary artery disease 38.26 9.98 314 334944 30482 55926327
Blood triglycerides increased 37.98 9.98 154 335104 11523 55945286
Macular degeneration 37.90 9.98 34 335224 18874 55937935
Cold sweat 37.75 9.98 147 335111 10796 55946013
Decreased appetite 37.69 9.98 1631 333627 217600 55739209
Multiple sclerosis relapse 37.49 9.98 139 335119 44764 55912045
Distributive shock 37.39 9.98 39 335219 1052 55955757
Accidental overdose 37.34 9.98 229 335029 20232 55936577
Neurotoxicity 37.29 9.98 24 335234 15771 55941038
Urine albumin/creatinine ratio abnormal 37.16 9.98 9 335249 0 55956809
Persistent cloaca 37.14 9.98 20 335238 185 55956624
Sedation complication 36.44 9.98 12 335246 11660 55945149
Left ventricular hypertrophy 36.24 9.98 87 335171 4897 55951912
Exposure via ingestion 35.97 9.98 62 335196 2746 55954063
Disease progression 35.44 9.98 428 334830 104745 55852064
Adenocarcinoma pancreas 35.30 9.98 38 335220 1064 55955745
Aphasia 35.08 9.98 305 334953 30110 55926699
Drug tolerance decreased 35.06 9.98 18 335240 13393 55943416
Joint range of motion decreased 34.76 9.98 61 335197 25304 55931505
Kussmaul respiration 34.67 9.98 20 335238 214 55956595
Hypophagia 34.58 9.98 292 334966 28584 55928225
Bursitis 34.57 9.98 70 335188 27512 55929297
Blood pH decreased 34.51 9.98 57 335201 2437 55954372
Rheumatoid nodule 34.50 9.98 23 335235 14834 55941975
Type 2 diabetes mellitus 34.13 9.98 428 334830 46434 55910375
Pregnancy 34.07 9.98 93 335165 32940 55923869
Product substitution issue 33.67 9.98 174 335084 14425 55942384
Immunodeficiency 33.67 9.98 28 335230 16129 55940680
Osteoporosis 33.28 9.98 178 335080 51874 55904935
Blood pressure systolic increased 33.26 9.98 381 334877 40455 55916354
Red blood cell sedimentation rate increased 32.83 9.98 110 335148 36513 55920296
Bone marrow failure 32.78 9.98 75 335183 28211 55928598
Cytokine release syndrome 32.54 9.98 12 335246 10863 55945946
High density lipoprotein decreased 32.48 9.98 46 335212 1716 55955093
Bladder sphincter atony 32.45 9.98 17 335241 148 55956661
Albuminuria 32.15 9.98 18 335240 181 55956628
Gastrointestinal disorder 32.03 9.98 475 334783 112227 55844582
Asthenia 31.75 9.98 2412 332846 340561 55616248
Enthesopathy 31.71 9.98 5 335253 8058 55948751
Diabetic ketosis 31.66 9.98 18 335240 187 55956622
Injection site reaction 31.38 9.98 187 335071 53060 55903749
Colitis ulcerative 31.35 9.98 61 335197 24330 55932479
Haematotoxicity 31.22 9.98 6 335252 8377 55948432
Drug abuse 31.20 9.98 255 335003 67355 55889454
Parkinsonism 31.13 9.98 126 335132 9420 55947389
Malignant neoplasm progression 31.09 9.98 284 334974 73303 55883506
Suspected suicide 31.08 9.98 87 335171 5379 55951430
Neutrophil count decreased 30.95 9.98 172 335086 49650 55907159
Acute myocardial infarction 30.60 9.98 296 334962 30097 55926712
Body mass index increased 30.51 9.98 35 335223 1053 55955756
Haemofiltration 30.51 9.98 8 335250 3 55956806
Posterior reversible encephalopathy syndrome 30.46 9.98 30 335228 15930 55940879
Ischaemic stroke 30.42 9.98 188 335070 16654 55940155
Multiple sclerosis 30.41 9.98 76 335182 27726 55929083
Intestinal malrotation 30.35 9.98 22 335236 357 55956452
Coordination abnormal 30.21 9.98 152 335106 12469 55944340
Allergic reaction to excipient 30.20 9.98 21 335237 318 55956491
Alveolar osteitis 30.13 9.98 26 335232 549 55956260
Pancreatitis chronic 29.84 9.98 51 335207 2243 55954566
Metabolic syndrome 29.66 9.98 39 335219 1354 55955455
Vitamin B12 decreased 29.52 9.98 60 335198 3015 55953794
Polymyalgia rheumatica 29.42 9.98 60 335198 3022 55953787
Anovulatory cycle 29.35 9.98 16 335242 152 55956657
Hospitalisation 29.33 9.98 295 334963 74705 55882104
Facet joint syndrome 29.24 9.98 3 335255 6714 55950095
Breast cancer stage III 29.20 9.98 4 335254 7159 55949650
Lupus-like syndrome 29.18 9.98 19 335239 12408 55944401
Injection site erythema 28.90 9.98 308 334950 77140 55879669
Blood phosphorus increased 28.86 9.98 56 335202 2720 55954089
Pancreatic mass 28.71 9.98 30 335228 811 55955998
Foreign body aspiration 28.61 9.98 17 335241 193 55956616
Disability 28.60 9.98 31 335227 15749 55941060
Pulmonary fibrosis 28.34 9.98 87 335171 29671 55927138
Grip strength decreased 28.30 9.98 33 335225 16223 55940586
Thirst 28.28 9.98 136 335122 10954 55945855
Pollakiuria 28.17 9.98 251 335007 24951 55931858
Therapeutic response decreased 28.16 9.98 191 335067 52567 55904242
Blood lactic acid 27.31 9.98 13 335245 90 55956719
Pain in jaw 27.24 9.98 134 335124 39902 55916907
Osmolar gap 27.07 9.98 13 335245 92 55956717
Insulin C-peptide decreased 27.06 9.98 9 335249 19 55956790
Hypovolaemia 26.75 9.98 122 335136 9613 55947196
Cholecystitis chronic 26.66 9.98 122 335136 9626 55947183
Conjoined twins 26.49 9.98 18 335240 262 55956547
Aspergillus infection 26.45 9.98 6 335252 7459 55949350
Epstein-Barr virus infection 26.43 9.98 6 335252 7457 55949352
Diabetic hyperosmolar coma 26.37 9.98 20 335238 349 55956460
Lung disorder 26.32 9.98 194 335064 52403 55904406
Infective pulmonary exacerbation of cystic fibrosis 26.15 9.98 8 335250 8149 55948660
Oedematous pancreatitis 26.04 9.98 22 335236 451 55956358
Platelet count decreased 26.03 9.98 461 334797 105922 55850887
Blood pressure systolic decreased 25.91 9.98 90 335168 6253 55950556
Glucose urine present 25.79 9.98 26 335232 673 55956136
Night sweats 25.76 9.98 142 335116 41071 55915738
Renal abscess 25.70 9.98 26 335232 676 55956133
Anaemia macrocytic 25.68 9.98 57 335201 3046 55953763
Shock hypoglycaemic 25.63 9.98 13 335245 105 55956704
Joint stiffness 25.61 9.98 116 335142 35309 55921500
Thrombotic microangiopathy 25.56 9.98 12 335246 9399 55947410
Headache 25.36 9.98 2929 332329 556115 55400694
Pancreatic injury 25.35 9.98 9 335249 25 55956784
Muscle necrosis 25.11 9.98 24 335234 581 55956228
Malabsorption 24.94 9.98 64 335194 3757 55953052
Body temperature decreased 24.89 9.98 189 335069 17919 55938890
Mucosal inflammation 24.88 9.98 151 335107 42659 55914150
Mechanical ventilation complication 24.78 9.98 6 335252 0 55956809
Needle issue 24.38 9.98 110 335148 8628 55948181
Dizziness 24.31 9.98 2577 332681 373563 55583246
Endometrial adenocarcinoma 24.25 9.98 33 335225 1185 55955624
Dysentery 24.24 9.98 27 335231 786 55956023
Breast cancer stage I 24.20 9.98 4 335254 6226 55950583
Lip dry 24.11 9.98 14 335244 9726 55947083
Temperature perception test abnormal 24.02 9.98 8 335250 17 55956792
Hyperhidrosis 24.00 9.98 732 334526 93356 55863453
Blood urea increased 23.98 9.98 237 335021 24236 55932573
Fungal infection 23.88 9.98 301 334957 32692 55924117
Bladder pain 23.83 9.98 41 335217 1813 55954996
Hyperinsulinaemia 23.76 9.98 12 335246 96 55956713
Apolipoprotein A-I decreased 23.71 9.98 8 335250 18 55956791
Angina pectoris 23.68 9.98 263 334995 27713 55929096
Progressive multifocal leukoencephalopathy 23.61 9.98 22 335236 11991 55944818
Malignant mediastinal neoplasm 23.53 9.98 28 335230 877 55955932
Pruritus genital 23.51 9.98 24 335234 631 55956178
Non-alcoholic steatohepatitis 23.45 9.98 36 335222 1445 55955364
Osmolar gap increased 23.42 9.98 8 335250 19 55956790
Tunnel vision 23.34 9.98 27 335231 820 55955989
Mouth ulceration 23.30 9.98 94 335164 29546 55927263
IIIrd nerve paresis 23.20 9.98 13 335245 131 55956678
Pulseless electrical activity 23.14 9.98 93 335165 6931 55949878
Hypoglycaemic unconsciousness 23.02 9.98 25 335233 707 55956102
Swollen tongue 22.96 9.98 279 334979 30045 55926764
Skin haemorrhage 22.79 9.98 105 335153 8308 55948501
Hepatic function abnormal 22.75 9.98 117 335141 34441 55922368
Blood growth hormone increased 22.73 9.98 20 335238 434 55956375
Congenital absence of bile ducts 22.34 9.98 8 335250 23 55956786
Increased appetite 22.19 9.98 107 335151 8628 55948181
Macular oedema 22.18 9.98 61 335197 3733 55953076
Pulmonary arterial hypertension 22.15 9.98 82 335176 26421 55930388
Bone density decreased 22.11 9.98 26 335232 12734 55944075
Diabetic foot 22.07 9.98 33 335225 1294 55955515
Blood insulin decreased 21.99 9.98 7 335251 12 55956797
Chorea 21.91 9.98 34 335224 1378 55955431
Urine output decreased 21.85 9.98 124 335134 10653 55946156
Bronchopulmonary aspergillosis 21.74 9.98 11 335247 8253 55948556
Base excess negative 21.74 9.98 6 335252 4 55956805
Cholestatic liver injury 21.69 9.98 44 335214 2208 55954601
Hyperinsulinaemic hypoglycaemia 21.66 9.98 10 335248 64 55956745
Carcinoid tumour of the stomach 21.63 9.98 13 335245 151 55956658
Glomerular filtration rate abnormal 21.46 9.98 24 335234 702 55956107
Unintentional medical device removal 21.36 9.98 4 335254 5690 55951119
Sedation 21.28 9.98 121 335137 34733 55922076
Mitochondrial enzyme deficiency 21.17 9.98 8 335250 28 55956781
Overweight 21.11 9.98 55 335203 3259 55953550
Insulin-like growth factor increased 21.10 9.98 26 335232 845 55955964
Postmenopausal haemorrhage 21.08 9.98 41 335217 1995 55954814
General physical health deterioration 20.94 9.98 814 334444 169196 55787613
Pathogen resistance 20.90 9.98 5 335253 5995 55950814
Diabetic ulcer 20.77 9.98 14 335244 201 55956608
CD30 expression 20.75 9.98 8 335250 30 55956779
Generalised tonic-clonic seizure 20.69 9.98 89 335169 27477 55929332
Multiple cardiac defects 20.65 9.98 5 335253 0 55956809
Hepatosplenomegaly neonatal 20.65 9.98 5 335253 0 55956809
Jaundice hepatocellular 20.55 9.98 8 335250 31 55956778
Cytomegalovirus viraemia 20.54 9.98 3 335255 5117 55951692
Herpes zoster 20.48 9.98 323 334935 75566 55881243
Pleural effusion 20.41 9.98 372 334886 85108 55871701
Medication error 20.36 9.98 360 334898 41975 55914834
Joint effusion 20.26 9.98 36 335222 14862 55941947
Congenital bladder anomaly 20.25 9.98 13 335245 171 55956638
Oxygen saturation immeasurable 20.18 9.98 6 335252 7 55956802
Maternal exposure timing unspecified 19.94 9.98 4 335254 5419 55951390
Incorrect route of product administration 19.85 9.98 63 335195 21266 55935543
Urachal abnormality 19.75 9.98 13 335245 179 55956630
Incorrect dose administered 19.60 9.98 430 334828 52117 55904692
Hyperventilation 19.59 9.98 76 335182 5572 55951237
Hypertensive crisis 19.58 9.98 147 335111 13889 55942920
Bronchostenosis 19.48 9.98 18 335240 417 55956392
Prothrombin consumption time prolonged 19.44 9.98 8 335250 37 55956772
Necrotising myositis 19.41 9.98 18 335240 419 55956390
Fall 19.39 9.98 2422 332836 355088 55601721
Wrong patient received product 19.25 9.98 41 335217 2130 55954679
Renal injury 19.18 9.98 104 335154 8783 55948026
Resuscitation 19.17 9.98 28 335230 1075 55955734
Metastases to retroperitoneum 19.08 9.98 12 335246 152 55956657
Crush syndrome 19.05 9.98 11 335247 118 55956691
Glucose tolerance impaired 19.03 9.98 74 335184 5431 55951378
Decreased bronchial secretion 18.95 9.98 9 335249 62 55956747
Epileptic encephalopathy 18.92 9.98 15 335243 280 55956529
Poisoning 18.90 9.98 136 335122 12677 55944132
Gait inability 18.85 9.98 352 334906 41466 55915343
Hyperphagia 18.84 9.98 34 335224 1562 55955247
Flatulence 18.77 9.98 276 334982 31012 55925797
Congenital aortic valve stenosis 18.71 9.98 9 335249 64 55956745
Osteoarthritis 18.69 9.98 351 334907 79945 55876864
Hypoparathyroidism 18.65 9.98 21 335237 619 55956190
Inappropriate antidiuretic hormone secretion 18.59 9.98 143 335115 13613 55943196
Skin ulcer 18.56 9.98 144 335114 38464 55918345
Clostridium difficile infection 18.52 9.98 91 335167 27107 55929702
Hypoglycaemia neonatal 18.41 9.98 25 335233 896 55955913
Animal scratch 18.40 9.98 27 335231 1041 55955768
Herpes simplex 18.34 9.98 11 335247 7507 55949302
Musculoskeletal disorder 18.22 9.98 56 335202 19091 55937718
Hypoglycaemic seizure 18.20 9.98 18 335240 455 55956354
Thyroglobulin increased 18.18 9.98 8 335250 45 55956764
Base excess decreased 18.14 9.98 9 335249 69 55956740
Acute myeloid leukaemia 18.09 9.98 47 335211 16925 55939884
Blood iron decreased 18.04 9.98 133 335125 12494 55944315
Product complaint 18.04 9.98 126 335132 11634 55945175
Blood ketone body 18.03 9.98 8 335250 46 55956763
Basilar artery thrombosis 17.92 9.98 11 335247 133 55956676
Thalamic infarction 17.92 9.98 18 335240 464 55956345
Genital infection fungal 17.88 9.98 12 335246 171 55956638
Urinary tract infection 17.87 9.98 1664 333594 238849 55717960
No adverse event 17.80 9.98 135 335123 36239 55920570
Atrioventricular block complete 17.76 9.98 90 335168 7404 55949405
Neuropathy, ataxia, retinitis pigmentosa syndrome 17.75 9.98 8 335250 48 55956761
Oral herpes 17.74 9.98 73 335185 22817 55933992
Stevens-Johnson syndrome 17.73 9.98 72 335186 22591 55934218
Creatinine renal clearance 17.73 9.98 5 335253 4 55956805
Deformity 17.66 9.98 21 335237 10234 55946575
Lymphocyte count decreased 17.60 9.98 96 335162 27843 55928966
Complication associated with device 17.55 9.98 41 335217 15309 55941500
Muscular weakness 17.46 9.98 775 334483 103677 55853132
Pancreatic enzymes increased 17.44 9.98 21 335237 666 55956143
Renal tubular disorder 17.43 9.98 43 335215 2463 55954346
Immune reconstitution inflammatory syndrome 17.42 9.98 6 335252 5668 55951141
Dry eye 17.27 9.98 133 335125 35583 55921226
Pulmonary toxicity 17.26 9.98 13 335245 7870 55948939
Bicuspid aortic valve 17.26 9.98 10 335248 108 55956701
Eyelid bleeding 17.25 9.98 7 335251 31 55956778
Vision blurred 17.24 9.98 630 334628 82313 55874496
Glycosuria 17.21 9.98 27 335231 1105 55955704
Creatinine renal clearance abnormal 17.20 9.98 16 335242 374 55956435
Nephrogenic systemic fibrosis 17.05 9.98 3 335255 4462 55952347
Pulmonary hypoplasia 17.02 9.98 14 335244 276 55956533
Dyslipidaemia 17.00 9.98 79 335179 6274 55950535
Salivary hypersecretion 16.94 9.98 85 335173 6965 55949844
Hypertensive heart disease 16.92 9.98 41 335217 2322 55954487
Febrile bone marrow aplasia 16.91 9.98 9 335249 6563 55950246
Bladder cancer 16.91 9.98 65 335193 4745 55952064
Antipsychotic drug level increased 16.88 9.98 50 335208 3192 55953617
Metastases to kidney 16.86 9.98 12 335246 189 55956620
Device related infection 16.82 9.98 70 335188 21810 55934999
Hormone receptor positive HER2 negative breast cancer 16.74 9.98 11 335247 151 55956658
Thyroid cancer recurrent 16.73 9.98 7 335251 34 55956775
Anion gap abnormal 16.73 9.98 15 335243 334 55956475
Myxoedema coma 16.65 9.98 16 335242 390 55956419
Congenital uterine anomaly 16.65 9.98 10 335248 116 55956693
Treatment noncompliance 16.62 9.98 280 334978 32343 55924466
Blood pressure inadequately controlled 16.62 9.98 62 335196 4462 55952347
Persistent left superior vena cava 16.57 9.98 7 335251 35 55956774
Accidental underdose 16.54 9.98 21 335237 704 55956105
Skinfold measurement 16.52 9.98 4 335254 0 55956809
Reactive psychosis 16.52 9.98 4 335254 0 55956809
Insulin resistant diabetes 16.52 9.98 4 335254 0 55956809
Pleural mesothelioma 16.52 9.98 4 335254 0 55956809
Blood lactic acid abnormal 16.52 9.98 4 335254 0 55956809
Autoimmune myositis 16.47 9.98 9 335249 86 55956723
Fluid intake reduced 16.46 9.98 50 335208 3237 55953572
Peritonitis 16.42 9.98 46 335212 16156 55940653
Ankylosing spondylitis 16.40 9.98 21 335237 9909 55946900
Differential white blood cell count abnormal 16.38 9.98 21 335237 711 55956098
Blood pressure increased 16.37 9.98 1038 334220 144138 55812671
Medullary thyroid cancer 16.36 9.98 10 335248 120 55956689
Device dislocation 16.35 9.98 74 335184 22532 55934277
Transient ischaemic attack 16.32 9.98 286 334972 33291 55923518
Breast cancer stage II 16.17 9.98 7 335251 5751 55951058
Visceral congestion 16.13 9.98 14 335244 298 55956511
Dysuria 16.12 9.98 265 334993 30464 55926345
Status epilepticus 16.09 9.98 42 335216 15099 55941710
Antipsychotic drug level decreased 16.05 9.98 14 335244 300 55956509
Cutaneous T-cell dyscrasia 16.05 9.98 8 335250 62 55956747
Prescription drug used without a prescription 15.97 9.98 36 335222 1944 55954865
Peripheral venous disease 15.95 9.98 22 335236 10057 55946752
Blood calcium decreased 15.91 9.98 80 335178 23689 55933120
Product blister packaging issue 15.91 9.98 11 335247 165 55956644
Musculoskeletal pain 15.86 9.98 365 334893 80787 55876022
Adrenal adenoma 15.84 9.98 23 335235 878 55955931
Joint dislocation 15.82 9.98 45 335213 15728 55941081
Monoclonal B-cell lymphocytosis 15.81 9.98 7 335251 40 55956769
Retinitis 15.78 9.98 3 335255 4221 55952588
Syncope 15.78 9.98 792 334466 107407 55849402
Cardiovascular disorder 15.73 9.98 115 335143 10774 55946035
Anion gap 15.72 9.98 26 335232 1113 55955696
Basal cell carcinoma 15.70 9.98 87 335171 25134 55931675
Chronic sinusitis 15.70 9.98 16 335242 8362 55948447
Constipation 15.70 9.98 1014 334244 200929 55755880
Athetosis 15.53 9.98 7 335251 42 55956767
Atrial fibrillation 15.45 9.98 795 334463 108102 55848707
Sprue-like enteropathy 15.42 9.98 18 335240 552 55956257
Sleep disorder 15.37 9.98 297 334961 67366 55889443
Hyperphosphataemia 15.31 9.98 36 335222 1999 55954810
Osteonecrosis of jaw 15.30 9.98 126 335132 33232 55923577
Lymphopenia 15.30 9.98 50 335208 16724 55940085
Alkalosis hypochloraemic 15.29 9.98 10 335248 136 55956673
Blood pressure diastolic decreased 15.16 9.98 179 335079 19144 55937665
Pyelonephritis 15.13 9.98 154 335104 15870 55940939
Heart sounds 15.10 9.98 21 335237 770 55956039
Panniculitis 15.06 9.98 22 335236 9820 55946989
Cardiac failure 15.04 9.98 615 334643 81478 55875331
Electrolyte imbalance 15.02 9.98 169 335089 17864 55938945
Urosepsis 15.00 9.98 159 335099 16557 55940252
Catheter site erythema 14.97 9.98 3 335255 4067 55952742
Hyponatraemic encephalopathy 14.96 9.98 12 335246 228 55956581
Ulcer 14.87 9.98 76 335182 22409 55934400
Pancreatic atrophy 14.87 9.98 10 335248 143 55956666
Diffuse large B-cell lymphoma 14.82 9.98 12 335246 7004 55949805
Pyelonephritis acute 14.81 9.98 58 335200 4271 55952538
Systemic infection 14.78 9.98 48 335210 3221 55953588
Liver disorder 14.77 9.98 181 335077 44189 55912620
Prolonged expiration 14.76 9.98 22 335236 860 55955949
Injection site mass 14.73 9.98 159 335099 16634 55940175
Myalgia 14.71 9.98 943 334315 131082 55825727
Bradyarrhythmia 14.68 9.98 35 335223 1961 55954848
Blood cholesterol decreased 14.67 9.98 22 335236 865 55955944
Adjustment disorder with depressed mood 14.66 9.98 6 335252 5097 55951712
Drug half-life increased 14.54 9.98 6 335252 28 55956781
Anal incontinence 14.53 9.98 124 335134 12174 55944635
Diabetic ketoacidotic hyperglycaemic coma 14.52 9.98 7 335251 50 55956759
Lower limb fracture 14.51 9.98 55 335203 17600 55939209
Transcription medication error 14.45 9.98 11 335247 193 55956616
Vitamin B6 deficiency 14.41 9.98 8 335250 79 55956730
Fat tissue increased 14.32 9.98 18 335240 597 55956212
Gallbladder oedema 14.31 9.98 11 335247 196 55956613
Diabetic cheiroarthropathy 14.30 9.98 4 335254 3 55956806
Diabetes mellitus management 14.30 9.98 4 335254 3 55956806
Retinopathy proliferative 14.29 9.98 7 335251 52 55956757
Blood electrolytes abnormal 14.27 9.98 23 335235 963 55955846
Foetal hypokinesia 14.25 9.98 16 335242 470 55956339
Retinal artery thrombosis 14.24 9.98 8 335250 81 55956728
Mental disability 14.24 9.98 8 335250 81 55956728
Low density lipoprotein increased 14.24 9.98 71 335187 5803 55951006
PCO2 decreased 14.22 9.98 26 335232 1207 55955602
Wound complication 14.21 9.98 46 335212 3082 55953727
Premature labour 14.18 9.98 31 335227 11851 55944958
Skin turgor decreased 14.17 9.98 16 335242 473 55956336
Abnormal loss of weight 14.15 9.98 66 335192 5250 55951559
Left atrial dilatation 14.12 9.98 32 335226 1734 55955075
Blood growth hormone abnormal 14.05 9.98 6 335252 31 55956778
Coeliac disease 14.04 9.98 25 335233 10314 55946495
Hypertensive angiopathy 13.92 9.98 8 335250 85 55956724
Eructation 13.89 9.98 85 335173 7503 55949306
Glucose urine 13.81 9.98 5 335253 15 55956794
Hereditary angioedema with normal C1 esterase inhibitor 13.77 9.98 4 335254 4 55956805
Venous aneurysm 13.77 9.98 4 335254 4 55956805
Diaphragmatic spasm 13.77 9.98 4 335254 4 55956805
Enterochromaffin cell hyperplasia 13.75 9.98 7 335251 57 55956752
Device difficult to use 13.75 9.98 27 335231 10734 55946075
Impaired work ability 13.74 9.98 140 335118 14432 55942377
Electrocardiogram QT prolonged 13.73 9.98 424 334834 54164 55902645
Bladder neoplasm 13.71 9.98 17 335241 556 55956253
Myocardial ischaemia 13.71 9.98 121 335137 11995 55944814
Brain stem infarction 13.71 9.98 20 335238 767 55956042
Blood chloride decreased 13.66 9.98 65 335193 5212 55951597
Skin disorder 13.66 9.98 96 335162 26213 55930596
Pelvic fracture 13.66 9.98 33 335225 12180 55944629
Tinnitus 13.54 9.98 114 335144 29928 55926881
Diabetic complication 13.52 9.98 21 335237 852 55955957
Sensorimotor disorder 13.51 9.98 15 335243 435 55956374
Coma scale abnormal 13.40 9.98 61 335197 4802 55952007
Urine albumin/creatinine ratio increased 13.39 9.98 12 335246 267 55956542
Cortisol increased 13.35 9.98 14 335244 380 55956429
Premature delivery 13.33 9.98 231 335027 26829 55929980
Adrenal neoplasm 13.33 9.98 13 335245 323 55956486
Hypereosinophilic syndrome 13.31 9.98 12 335246 269 55956540
Hypoperfusion 13.20 9.98 27 335231 1363 55955446
Hypertriglyceridaemia 13.19 9.98 69 335189 5747 55951062
Red cell distribution width abnormal 13.19 9.98 9 335249 132 55956677
Cutaneous vasculitis 13.18 9.98 60 335198 4724 55952085
Heart rate increased 13.07 9.98 614 334644 82659 55874150
Diet failure 13.05 9.98 6 335252 38 55956771
Sinus arrest 13.02 9.98 31 335227 1736 55955073
Flushing 12.94 9.98 318 334940 69782 55887027
Peripheral artery haematoma 12.92 9.98 6 335252 39 55956770
Benign pancreatic neoplasm 12.92 9.98 5 335253 19 55956790
Osteonecrosis 12.91 9.98 83 335175 23132 55933677
Sinus disorder 12.87 9.98 184 335074 20550 55936259
Tumour lysis syndrome 12.83 9.98 17 335241 7906 55948903
Peripheral circulatory failure 12.81 9.98 21 335237 892 55955917
Hypergastrinaemia 12.81 9.98 8 335250 100 55956709
Bundle branch block left 12.76 9.98 73 335185 6289 55950520
Autoimmune nephritis 12.76 9.98 13 335245 341 55956468
Product administration error 12.70 9.98 185 335073 20744 55936065
Wound infection 12.70 9.98 47 335211 15146 55941663
Food craving 12.68 9.98 28 335230 1491 55955318
Binge eating 12.59 9.98 14 335244 407 55956402
Hypervolaemia 12.57 9.98 99 335159 26359 55930450
Coronary artery occlusion 12.56 9.98 84 335174 7645 55949164
Multiple-drug resistance 12.56 9.98 4 335254 3970 55952839
Blood osmolarity abnormal 12.51 9.98 4 335254 7 55956802
Choking 12.42 9.98 94 335164 8903 55947906
Non-high-density lipoprotein cholesterol decreased 12.39 9.98 3 335255 0 55956809
Electrocardiogram abnormal 12.34 9.98 87 335171 8057 55948752
Tumour compression 12.32 9.98 6 335252 44 55956765
Staphylococcal infection 12.32 9.98 154 335104 37464 55919345
Cell death 12.30 9.98 36 335222 2283 55954526
Gingival oedema 12.29 9.98 7 335251 73 55956736
Ectopia cordis 12.29 9.98 7 335251 73 55956736
Retching 12.29 9.98 129 335129 13401 55943408
Drug ineffective for unapproved indication 12.27 9.98 96 335162 25597 55931212
Nodular rash 12.25 9.98 10 335248 195 55956614
Blood urea abnormal 12.23 9.98 17 335241 623 55956186
Renal replacement therapy 12.21 9.98 7 335251 74 55956735
Creatinine renal clearance decreased 12.20 9.98 45 335213 14514 55942295
Foreign body in reproductive tract 12.18 9.98 15 335243 487 55956322
Hyperparathyroidism secondary 12.18 9.98 26 335232 1353 55955456
Cholangiectasis acquired 12.17 9.98 4 335254 8 55956801
Psychogenic tremor 12.17 9.98 5 335253 23 55956786
Cardiac failure congestive 12.15 9.98 639 334619 87081 55869728
Neurofibrosarcoma 12.06 9.98 9 335249 153 55956656
Blindness 12.05 9.98 165 335093 18256 55938553
Body temperature increased 12.05 9.98 138 335120 34104 55922705
Blindness cortical 12.02 9.98 15 335243 494 55956315
Pneumonia viral 11.96 9.98 15 335243 7143 55949666
Device use error 11.94 9.98 9 335249 5447 55951362
Neuroendocrine tumour 11.94 9.98 18 335240 711 55956098
Synovial cyst 11.88 9.98 23 335235 9191 55947618
Microcytic anaemia 11.86 9.98 44 335214 3158 55953651
Ear infection 11.86 9.98 124 335134 31171 55925638
Maximal voluntary ventilation abnormal 11.84 9.98 5 335253 25 55956784
Thirst decreased 11.83 9.98 11 335247 257 55956552
Ascites 11.81 9.98 155 335103 37389 55919420
Haemoglobin increased 11.78 9.98 45 335213 3275 55953534
Pancreatic neoplasm 11.77 9.98 18 335240 720 55956089
Glycosylated haemoglobin 11.74 9.98 7 335251 80 55956729
Product size issue 11.71 9.98 12 335246 317 55956492
Demyelination 11.69 9.98 12 335246 6250 55950559
Insulin-like growth factor decreased 11.66 9.98 13 335245 379 55956430
Angioplasty 11.63 9.98 25 335233 1307 55955502
Duodenal ulcer haemorrhage 11.61 9.98 35 335223 2257 55954552
Neoplasm malignant 11.60 9.98 104 335154 26951 55929858
Rash erythematous 11.59 9.98 154 335104 37067 55919742
Hypocalcaemia 11.58 9.98 238 335020 28522 55928287
Hypertensive emergency 11.56 9.98 28 335230 1585 55955224
Metabolic encephalopathy 11.54 9.98 62 335196 5218 55951591
Genital rash 11.53 9.98 14 335244 448 55956361
Vitreous haemorrhage 11.50 9.98 31 335227 1875 55954934
Blood pressure abnormal 11.37 9.98 128 335130 13532 55943277
Genital swelling 11.35 9.98 8 335250 124 55956685
Erythromelalgia 11.35 9.98 8 335250 124 55956685
Dystonia 11.34 9.98 37 335221 12384 55944425
Respiratory tract infection 11.32 9.98 149 335109 35922 55920887
Pancreatic failure 11.30 9.98 20 335238 905 55955904
Atelectasis 11.27 9.98 68 335190 19240 55937569
Scleritis 11.27 9.98 4 335254 3707 55953102
Gastrointestinal toxicity 11.26 9.98 12 335246 6144 55950665
Necrotising fasciitis 11.26 9.98 39 335219 2706 55954103
Gallbladder disorder 11.23 9.98 155 335103 17179 55939630
Intestinal perforation 11.19 9.98 31 335227 10928 55945881
Metastases to central nervous system 11.19 9.98 36 335222 12100 55944709
Rash maculo-papular 11.17 9.98 114 335144 28793 55928016
Duodenal ulcer 11.17 9.98 77 335181 7078 55949731
Wrong dose 11.17 9.98 21 335237 996 55955813
Lactate pyruvate ratio increased 11.11 9.98 7 335251 89 55956720
Diabetic foot infection 11.05 9.98 9 335249 175 55956634
Pancreatic pseudocyst 11.01 9.98 15 335243 539 55956270
Exercise tolerance decreased 11.00 9.98 60 335198 5078 55951731
Central nervous system lesion 11.00 9.98 27 335231 9911 55946898
Product solubility abnormal 10.99 9.98 18 335240 764 55956045
Urine output increased 10.99 9.98 23 335235 1180 55955629
Intestinal obstruction 10.94 9.98 110 335148 27861 55928948
Clostridium difficile colitis 10.94 9.98 66 335192 18672 55938137
Urine ketone body 10.92 9.98 8 335250 132 55956677
Injection site swelling 10.92 9.98 188 335070 43390 55913419
Biopsy skin abnormal 10.91 9.98 7 335251 92 55956717
Sinonasal obstruction 10.88 9.98 10 335248 230 55956579
Blood insulin increased 10.87 9.98 8 335250 133 55956676
Grandiosity 10.87 9.98 11 335247 286 55956523
Transferrin saturation decreased 10.86 9.98 16 335242 619 55956190
Abdominal distension 10.86 9.98 566 334692 77060 55879749
Vulvovaginal mycotic infection 10.86 9.98 58 335200 4870 55951939
Serotonin syndrome 10.85 9.98 103 335155 26387 55930422
Macrosomia 10.83 9.98 6 335252 59 55956750
Ear congestion 10.81 9.98 33 335225 2142 55954667
Aerophagia 10.81 9.98 4 335254 13 55956796
Malignant polyp 10.79 9.98 9 335249 181 55956628
Prescribed overdose 10.79 9.98 83 335175 22213 55934596
Blood sodium increased 10.78 9.98 36 335222 2452 55954357
Incision site swelling 10.77 9.98 8 335250 135 55956674
Hunger 10.76 9.98 56 335202 4655 55952154
Spinal compression fracture 10.74 9.98 41 335217 13093 55943716
Respiratory syncytial virus infection 10.73 9.98 10 335248 5451 55951358
Confusional state 10.73 9.98 1406 333852 206749 55750060
Genital infection female 10.72 9.98 7 335251 95 55956714
Colitis microscopic 10.72 9.98 82 335176 7793 55949016
Large intestine polyp 10.71 9.98 80 335178 7547 55949262
Femur fracture 10.68 9.98 167 335091 39128 55917681
Tuberculosis 10.68 9.98 32 335226 10997 55945812
Large intestine perforation 10.65 9.98 19 335239 7832 55948977
Hepatic failure 10.64 9.98 268 334990 33218 55923591
Encephalitis 10.60 9.98 20 335238 8070 55948739
Injection site hypertrophy 10.58 9.98 6 335252 62 55956747
Oedema 10.57 9.98 390 334868 81530 55875279
Pneumothorax 10.55 9.98 49 335209 14818 55941991
Pulmonary haemorrhage 10.54 9.98 15 335243 6768 55950041
Vulvovaginal pruritus 10.54 9.98 38 335220 2690 55954119
Pneumonia aspiration 10.49 9.98 133 335125 32278 55924531
Lymphadenopathy 10.48 9.98 147 335111 35061 55921748
Drug level abnormal 10.47 9.98 7 335251 99 55956710
Retinal vascular disorder 10.47 9.98 9 335249 189 55956620
Hypoplastic left heart syndrome 10.43 9.98 9 335249 190 55956619
Insulin C-peptide increased 10.42 9.98 6 335252 64 55956745
Cytomegalovirus infection reactivation 10.39 9.98 3 335255 3173 55953636
Empty sella syndrome 10.34 9.98 5 335253 36 55956773
Vascular stenosis 10.33 9.98 11 335247 304 55956505
Diffuse idiopathic skeletal hyperostosis 10.33 9.98 3 335255 3 55956806
Nipple swelling 10.33 9.98 3 335255 3 55956806
Aerococcus urinae infection 10.33 9.98 3 335255 3 55956806
Clear cell endometrial carcinoma 10.33 9.98 3 335255 3 55956806
Castleman's disease 10.33 9.98 3 335255 3 55956806
CSF volume increased 10.33 9.98 3 335255 3 55956806
Bicytopenia 10.27 9.98 32 335226 2101 55954708
Neutropenic sepsis 10.23 9.98 51 335207 15134 55941675
Product dispensing error 10.22 9.98 92 335166 9172 55947637
Bradyphrenia 10.19 9.98 71 335187 6549 55950260
Hypogammaglobulinaemia 10.19 9.98 14 335244 6412 55950397
Disorientation 10.19 9.98 288 334970 36325 55920484
Lichen planus 10.19 9.98 32 335226 2110 55954699
Genital infection 10.18 9.98 6 335252 67 55956742
Injury 10.12 9.98 275 334983 59576 55897233
Infected dermal cyst 10.12 9.98 13 335245 441 55956368
Cerebellar ischaemia 10.11 9.98 5 335253 38 55956771
Vulvovaginitis 10.10 9.98 11 335247 312 55956497
Post procedural sepsis 10.09 9.98 9 335249 199 55956610
Vulvovaginal discomfort 10.07 9.98 32 335226 2123 55954686
Pleural fibrosis 10.05 9.98 4 335254 3455 55953354
Increased viscosity of bronchial secretion 10.04 9.98 10 335248 255 55956554
Blood immunoglobulin E increased 10.04 9.98 40 335218 2969 55953840
Intestinal transit time abnormal 10.03 9.98 6 335252 69 55956740
Scleroderma 10.01 9.98 9 335249 4992 55951817
Pancreatic cyst 10.01 9.98 25 335233 1443 55955366
Metastases to fallopian tube 10.01 9.98 5 335253 39 55956770

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 9982.69 11.14 5126 279481 26811 31385926
Acute kidney injury 1984.48 11.14 6250 278357 273464 31139273
Hypoglycaemia 1926.82 11.14 2330 282277 48616 31364121
Metabolic acidosis 1611.35 11.14 1880 282727 37697 31375040
Diabetic ketoacidosis 1507.83 11.14 1235 283372 15670 31397067
Blood glucose increased 1143.66 11.14 2003 282604 59080 31353657
Euglycaemic diabetic ketoacidosis 780.53 11.14 421 284186 2453 31410284
Glycosylated haemoglobin increased 762.08 11.14 679 283928 9721 31403016
Diabetes mellitus inadequate control 723.21 11.14 722 283885 12019 31400718
Hyperkalaemia 669.62 11.14 1658 282949 62693 31350044
Ketoacidosis 513.10 11.14 360 284247 3552 31409185
Pancreatitis 479.54 11.14 1019 283588 34752 31377985
Hyperglycaemia 472.81 11.14 1025 283582 35451 31377286
Off label use 407.20 11.14 1673 282934 345601 31067136
Pancreatitis acute 355.51 11.14 740 283867 24860 31387877
Hyperlactacidaemia 353.53 11.14 250 284357 2500 31410237
Drug abuse 317.11 11.14 198 284409 87560 31325177
Pemphigoid 260.82 11.14 346 284261 7925 31404812
Blood lactic acid increased 260.47 11.14 298 284309 5832 31406905
Febrile neutropenia 255.87 11.14 438 284169 121411 31291326
Diabetic metabolic decompensation 255.48 11.14 169 284438 1500 31411237
Shock 245.33 11.14 593 284014 22052 31390685
Diabetes mellitus 245.08 11.14 890 283717 41666 31371071
Hypoglycaemic coma 225.08 11.14 175 284432 2046 31410691
Blood glucose abnormal 221.62 11.14 257 284350 5106 31407631
Completed suicide 218.08 11.14 1488 283119 90026 31322711
Death 212.02 11.14 2144 282463 358425 31054312
Pyrexia 204.62 11.14 1746 282861 302094 31110643
Neutropenia 201.21 11.14 620 283987 139744 31272993
Blood glucose fluctuation 193.43 11.14 205 284402 3670 31409067
Drug ineffective 193.36 11.14 2452 282155 393121 31019616
Intentional overdose 185.33 11.14 800 283807 40589 31372148
Type 2 diabetes mellitus 184.12 11.14 409 284198 14375 31398362
Blood glucose decreased 183.13 11.14 369 284238 12102 31400635
Product use in unapproved indication 170.77 11.14 400 284207 98771 31313966
Pneumonia 161.56 11.14 2084 282523 333228 31079509
Pancreatic carcinoma 154.12 11.14 277 284330 8323 31404414
Anuria 138.90 11.14 286 284321 9528 31403209
Platelet count decreased 135.04 11.14 522 284085 109913 31302824
Acidosis 133.94 11.14 284 284323 9662 31403075
Thrombocytopenia 131.38 11.14 748 283859 141999 31270738
Vitamin B12 deficiency 131.17 11.14 160 284447 3359 31409378
Cytomegalovirus infection 129.90 11.14 31 284576 24676 31388061
Ketonuria 125.85 11.14 74 284533 521 31412216
Diabetic neuropathy 118.09 11.14 161 284446 3788 31408949
Seizure 116.62 11.14 480 284127 99288 31313449
Drug resistance 114.64 11.14 34 284573 23419 31389318
Leukopenia 113.95 11.14 216 284391 57612 31355125
Pancytopenia 113.74 11.14 402 284205 86914 31325823
Plasma cell myeloma 113.29 11.14 209 284398 56322 31356415
Weight decreased 109.28 11.14 2030 282577 157922 31254815
White blood cell count decreased 106.88 11.14 413 284194 86985 31325752
Renal failure 104.91 11.14 1622 282985 121708 31291029
Continuous haemodiafiltration 104.43 11.14 79 284528 884 31411853
Infusion related reaction 104.19 11.14 169 284438 47886 31364851
Toxicity to various agents 100.68 11.14 2233 282374 179254 31233483
Rheumatoid arthritis 98.26 11.14 174 284433 47635 31365102
Vomiting 97.71 11.14 2667 281940 221306 31191431
Hypomagnesaemia 96.77 11.14 383 284224 18675 31394062
Diarrhoea 96.69 11.14 3973 280634 348436 31064301
Anion gap increased 95.95 11.14 96 284511 1601 31411136
Disease progression 95.56 11.14 452 284155 90012 31322725
Bone marrow failure 94.61 11.14 68 284539 27940 31384797
Drug dependence 93.10 11.14 43 284564 22536 31390201
Stomatitis 84.28 11.14 140 284467 39298 31373439
Haemodialysis 84.14 11.14 239 284368 9806 31402931
Immune-mediated myositis 83.74 11.14 93 284514 1759 31410978
Injection site nodule 82.58 11.14 84 284523 1430 31411307
MELAS syndrome 80.82 11.14 25 284582 16 31412721
Ketosis 80.31 11.14 51 284556 419 31412318
Toxic epidermal necrolysis 79.24 11.14 38 284569 19486 31393251
Pneumocystis jirovecii pneumonia 78.02 11.14 33 284574 18218 31394519
Graft versus host disease 77.20 11.14 4 284603 10443 31402294
Distributive shock 76.69 11.14 70 284537 1035 31411702
Treatment failure 76.35 11.14 157 284450 40635 31372102
Malignant neoplasm progression 75.84 11.14 408 284199 78590 31334147
Dehydration 74.88 11.14 1493 283114 117618 31295119
Neutrophil count decreased 74.40 11.14 194 284413 46200 31366537
Lipase increased 71.74 11.14 208 284399 8635 31404102
Product residue present 69.40 11.14 101 284506 2529 31410208
Bladder cancer 68.48 11.14 288 284319 14437 31398300
Intentional product use issue 68.44 11.14 221 284386 49126 31363611
Drug level increased 66.30 11.14 357 284250 19829 31392908
Urine ketone body present 66.27 11.14 64 284543 1020 31411717
Blood lactic acid 65.32 11.14 40 284567 306 31412431
Glomerular filtration rate decreased 64.77 11.14 244 284363 11621 31401116
Polyuria 64.04 11.14 184 284423 7599 31405138
Neuropathy peripheral 63.41 11.14 408 284199 75241 31337496
Suicide attempt 61.65 11.14 557 284050 36691 31376046
Myocardial infarction 61.55 11.14 1392 283215 112062 31300675
Overdose 59.96 11.14 1081 283526 83583 31329154
Diabetic retinopathy 57.68 11.14 73 284534 1593 31411144
Myocardial ischaemia 57.64 11.14 299 284308 16368 31396369
Suspected suicide 57.30 11.14 119 284488 3988 31408749
Hypothermia 56.93 11.14 202 284405 9342 31403395
Macroangiopathy 56.83 11.14 16 284591 3 31412734
Blood pH decreased 55.19 11.14 82 284525 2093 31410644
Mucosal inflammation 55.16 11.14 144 284463 34283 31378454
Anxiety 54.92 11.14 537 284070 90496 31322241
Latent autoimmune diabetes in adults 54.83 11.14 21 284586 44 31412693
Myelosuppression 54.75 11.14 33 284574 14887 31397850
Aspergillus infection 54.03 11.14 18 284589 11510 31401227
Transplant rejection 53.41 11.14 11 284596 9697 31403040
Condition aggravated 53.14 11.14 1096 283511 162913 31249824
Aggression 53.12 11.14 165 284442 37126 31375611
Pancreatic carcinoma metastatic 52.97 11.14 95 284512 2849 31409888
Sepsis 52.92 11.14 1003 283604 150926 31261811
Posterior reversible encephalopathy syndrome 52.82 11.14 10 284597 9357 31403380
Glycosylated haemoglobin abnormal 52.65 11.14 26 284581 122 31412615
Toe amputation 52.51 11.14 81 284526 2139 31410598
Exposure via ingestion 52.33 11.14 77 284530 1948 31410789
Hypotension 52.06 11.14 2290 282317 202328 31210409
Pathogen resistance 51.90 11.14 8 284599 8693 31404044
Product odour abnormal 51.12 11.14 46 284561 667 31412070
Hepatic function abnormal 50.86 11.14 194 284413 41028 31371709
Bronchopulmonary aspergillosis 50.25 11.14 30 284577 13604 31399133
Kidney transplant rejection 50.22 11.14 4 284603 7278 31405459
Hospitalisation 49.59 11.14 254 284353 49553 31363184
Diabetic nephropathy 49.58 11.14 75 284532 1946 31410791
Progressive multifocal leukoencephalopathy 49.54 11.14 11 284596 9202 31403535
Acetonaemia 49.53 11.14 25 284582 124 31412613
Coronary artery disease 49.11 11.14 631 283976 45456 31367281
Balanoposthitis 48.96 11.14 55 284552 1054 31411683
Pancreatitis chronic 48.89 11.14 77 284530 2071 31410666
Microalbuminuria 48.62 11.14 44 284563 643 31412094
Deep vein thrombosis 48.16 11.14 333 284274 60403 31352334
Product use issue 48.13 11.14 305 284302 56454 31356283
Alanine aminotransferase increased 46.89 11.14 436 284171 74220 31338517
Infective pulmonary exacerbation of cystic fibrosis 46.33 11.14 3 284604 6481 31406256
Obesity 46.20 11.14 210 284397 10890 31401847
Immune reconstitution inflammatory syndrome 45.55 11.14 9 284598 8169 31404568
Anaemia vitamin B12 deficiency 45.49 11.14 32 284575 317 31412420
Aspartate aminotransferase increased 45.35 11.14 353 284254 62366 31350371
Drug interaction 45.17 11.14 2297 282310 206246 31206491
Rash 45.00 11.14 1422 283185 200064 31212673
Blood ketone body increased 44.76 11.14 34 284573 383 31412354
Urine albumin/creatinine ratio abnormal 44.66 11.14 12 284595 0 31412737
Product monitoring error 44.36 11.14 94 284513 3196 31409541
Anion gap 44.09 11.14 43 284564 694 31412043
Haemophagocytic lymphohistiocytosis 44.02 11.14 25 284582 11653 31401084
Drug intolerance 42.89 11.14 282 284325 51751 31360986
Depression 42.88 11.14 566 284041 90249 31322488
Post transplant lymphoproliferative disorder 42.86 11.14 3 284604 6073 31406664
Interstitial lung disease 42.82 11.14 349 284258 61054 31351683
Diabetic ketoacidotic hyperglycaemic coma 42.77 11.14 23 284584 133 31412604
Infection 42.67 11.14 500 284107 81431 31331306
Diabetic foot infection 41.75 11.14 39 284568 595 31412142
Drug reaction with eosinophilia and systemic symptoms 41.22 11.14 135 284472 29883 31382854
Adenocarcinoma pancreas 41.14 11.14 55 284552 1269 31411468
Arthralgia 40.83 11.14 1041 283566 150383 31262354
Hypoxia 40.81 11.14 274 284333 50039 31362698
Pseudomonas infection 40.75 11.14 26 284581 11375 31401362
Renal tubular necrosis 40.59 11.14 249 284358 14510 31398227
Cytomegalovirus viraemia 40.54 11.14 6 284601 6719 31406018
Blood bicarbonate decreased 40.36 11.14 75 284532 2313 31410424
Epstein-Barr virus infection 40.12 11.14 7 284600 6946 31405791
Septic shock 40.00 11.14 390 284217 65768 31346969
Clostridium difficile infection 39.12 11.14 59 284548 17220 31395517
Therapeutic product effect decreased 38.89 11.14 149 284458 31473 31381264
Haemorrhage 38.78 11.14 257 284350 47077 31365660
Aplastic anaemia 38.76 11.14 17 284590 9186 31403551
Thirst 38.71 11.14 140 284467 6536 31406201
Glycosylated haemoglobin decreased 38.70 11.14 30 284577 349 31412388
Pancreatic neoplasm 38.03 11.14 43 284564 830 31411907
Therapy non-responder 38.02 11.14 165 284442 33646 31379091
Drug hypersensitivity 37.44 11.14 444 284163 72155 31340582
Osmolar gap increased 37.22 11.14 10 284597 0 31412737
Coma 37.15 11.14 547 284060 40603 31372134
Neurotoxicity 37.13 11.14 55 284552 16171 31396566
Genital infection fungal 36.95 11.14 22 284585 159 31412578
Exposure during pregnancy 36.03 11.14 16 284591 8582 31404155
Hyperglycaemic hyperosmolar nonketotic syndrome 35.79 11.14 48 284559 1111 31411626
Low density lipoprotein abnormal 35.70 11.14 27 284580 302 31412435
Hepatic steatosis 35.64 11.14 259 284348 15980 31396757
Osmolar gap 35.00 11.14 13 284594 24 31412713
Staphylococcal infection 34.74 11.14 149 284458 30483 31382254
Acute myocardial infarction 34.58 11.14 645 283962 50178 31362559
Polydipsia 34.43 11.14 89 284518 3451 31409286
Syncope 34.11 11.14 1004 283603 84178 31328559
Blood cholesterol 33.84 11.14 22 284585 189 31412548
Cytokine release syndrome 33.79 11.14 61 284546 16581 31396156
Obstructive pancreatitis 33.79 11.14 30 284577 427 31412310
Diabetic ketosis 33.76 11.14 18 284589 102 31412635
Haematotoxicity 33.70 11.14 11 284596 7126 31405611
Hallucination 33.64 11.14 261 284346 46149 31366588
Haemodynamic instability 33.31 11.14 159 284448 8416 31404321
Abdominal pain 33.29 11.14 1616 282991 144336 31268401
Myelodysplastic syndrome 32.80 11.14 78 284529 19173 31393564
Urine ketone body 32.37 11.14 14 284593 45 31412692
Foetal exposure during pregnancy 31.96 11.14 225 284382 40651 31372086
Vitamin B12 decreased 31.86 11.14 44 284563 1048 31411689
Insomnia 31.79 11.14 630 283977 94206 31318531
Anaemia 31.76 11.14 1580 283027 211942 31200795
Naevus flammeus 31.61 11.14 19 284588 140 31412597
Cardiovascular disorder 31.57 11.14 167 284440 9211 31403526
Neoplasm progression 31.56 11.14 86 284521 20186 31392551
Ascites 31.46 11.14 227 284380 40786 31371951
Appendicitis 31.29 11.14 34 284573 11431 31401306
Starvation ketoacidosis 31.21 11.14 13 284594 37 31412700
Cytopenia 30.77 11.14 32 284575 10978 31401759
Lumbosacral radiculoplexus neuropathy 30.76 11.14 12 284595 27 31412710
Haemoptysis 30.45 11.14 167 284440 32022 31380715
Blood ketone body 30.27 11.14 15 284592 71 31412666
Glycosuria 30.10 11.14 45 284562 1155 31411582
Cholelithiasis 30.06 11.14 287 284320 19192 31393545
Multiple-drug resistance 29.44 11.14 3 284604 4477 31408260
Dystonia 29.40 11.14 29 284578 10196 31402541
Acute myeloid leukaemia 29.22 11.14 79 284528 18593 31394144
Chills 29.13 11.14 479 284128 73671 31339066
Osteonecrosis 28.99 11.14 50 284557 13834 31398903
Sinusitis 28.68 11.14 202 284405 36494 31376243
Haemoglobin decreased 28.66 11.14 781 283826 111894 31300843
Tongue oedema 28.59 11.14 70 284537 2623 31410114
5-hydroxyindolacetic acid in urine increased 28.58 11.14 21 284586 224 31412513
Bradyarrhythmia 28.49 11.14 60 284547 2031 31410706
Glucose urine present 28.28 11.14 40 284567 975 31411762
Diabetic foot 28.23 11.14 65 284542 2340 31410397
Blood mercury abnormal 28.11 11.14 20 284587 202 31412535
No adverse event 27.82 11.14 87 284520 19538 31393199
Disseminated intravascular coagulation 27.76 11.14 93 284514 20444 31392293
Musculoskeletal stiffness 27.39 11.14 238 284369 41087 31371650
Antipsychotic drug level decreased 27.31 11.14 37 284570 865 31411872
Acute coronary syndrome 26.94 11.14 202 284405 12587 31400150
Pneumothorax 26.88 11.14 71 284536 16839 31395898
Bladder transitional cell carcinoma 26.84 11.14 66 284541 2480 31410257
Osteoporosis 26.76 11.14 39 284568 11544 31401193
Cardiac failure 26.66 11.14 983 283624 84970 31327767
Epilepsy 26.61 11.14 98 284509 20943 31391794
Diabetic eye disease 26.57 11.14 12 284595 44 31412693
Tumour lysis syndrome 26.48 11.14 62 284545 15323 31397414
Dizziness 26.40 11.14 2103 282504 197044 31215693
Drug level above therapeutic 26.09 11.14 83 284524 3627 31409110
Stevens-Johnson syndrome 26.07 11.14 75 284532 17297 31395440
Alveolar capillary dysplasia 26.05 11.14 7 284600 0 31412737
Diabetic macroangiopathy 25.94 11.14 8 284599 5 31412732
Vitamin B1 deficiency 25.90 11.14 22 284585 294 31412443
Synovitis 25.86 11.14 44 284563 12239 31400498
Status epilepticus 25.83 11.14 43 284564 12063 31400674
Hyperlipasaemia 25.75 11.14 27 284580 477 31412260
Acquired phimosis 25.68 11.14 13 284594 65 31412672
Clostridium difficile colitis 25.53 11.14 55 284552 14001 31398736
Rectal haemorrhage 25.46 11.14 206 284401 36098 31376639
Peritonitis 25.40 11.14 63 284544 15264 31397473
Osteonecrosis of jaw 25.40 11.14 74 284533 16997 31395740
Therapeutic response decreased 25.36 11.14 137 284470 26372 31386365
Anaemia megaloblastic 25.29 11.14 18 284589 182 31412555
Haematuria 24.99 11.14 568 284039 45746 31366991
Colitis ulcerative 24.98 11.14 84 284523 18445 31394292
Neoplasm malignant 24.72 11.14 87 284520 18844 31393893
Substance abuse 24.67 11.14 17 284590 7141 31405596
Therapeutic product effect incomplete 24.58 11.14 262 284345 43434 31369303
Needle issue 24.41 11.14 103 284504 5170 31407567
Psychotic disorder 24.33 11.14 110 284497 22183 31390554
Lymphocyte count decreased 24.30 11.14 99 284508 20550 31392187
Pancreatic pseudocyst 24.25 11.14 33 284574 775 31411962
Cerebrovascular accident 24.16 11.14 907 283700 78577 31334160
Coma scale abnormal 24.12 11.14 81 284526 3642 31409095
Angina pectoris 24.06 11.14 387 284220 29254 31383483
Suicidal ideation 23.98 11.14 210 284397 36196 31376541
Hyperoxaluria 23.75 11.14 15 284592 122 31412615
Drug ineffective for unapproved indication 23.74 11.14 81 284526 17709 31395028
Nausea 23.71 11.14 3133 281474 304814 31107923
Type V hyperlipidaemia 23.62 11.14 31 284576 702 31412035
Pulmonary haemorrhage 23.59 11.14 31 284576 9584 31403153
Medication error 23.50 11.14 310 284297 22462 31390275
Immunosuppressant drug level increased 23.49 11.14 9 284598 5276 31407461
Drug level below therapeutic 23.45 11.14 8 284599 5040 31407697
Gangrene 23.43 11.14 90 284517 4326 31408411
Burkholderia pseudomallei infection 23.39 11.14 10 284597 31 31412706
Vitreous haemorrhage 23.23 11.14 57 284550 2139 31410598
Tongue disorder 23.22 11.14 8 284599 5009 31407728
Dysphagia 23.17 11.14 371 284236 57305 31355432
Neuropathic arthropathy 23.12 11.14 16 284591 154 31412583
Migraine 22.95 11.14 59 284548 14121 31398616
Abdominal discomfort 22.92 11.14 616 283991 50951 31361786
Malaise 22.73 11.14 1782 282825 166729 31246008
Joint swelling 22.72 11.14 340 284267 53091 31359646
Tenosynovitis 22.69 11.14 5 284602 4205 31408532
Renal impairment 22.69 11.14 970 283637 85379 31327358
Enterococcal infection 22.62 11.14 27 284580 8704 31404033
Pollakiuria 22.52 11.14 253 284354 17649 31395088
Blood triglycerides increased 22.50 11.14 201 284406 13196 31399541
C-reactive protein abnormal 22.37 11.14 22 284585 7747 31404990
Clear cell renal cell carcinoma 22.35 11.14 37 284570 1039 31411698
Pancreatic neuroendocrine tumour 22.29 11.14 21 284586 324 31412413
Cornea verticillata 22.28 11.14 10 284597 36 31412701
Staphylococcal bacteraemia 22.17 11.14 21 284586 7527 31405210
Unevaluable event 22.13 11.14 172 284435 30403 31382334
Renal artery thrombosis 22.11 11.14 20 284587 292 31412445
Pleural effusion 22.09 11.14 508 284099 74412 31338325
Thrombotic microangiopathy 22.08 11.14 31 284576 9320 31403417
Flushing 22.03 11.14 169 284438 29959 31382778
Expired product administered 22.00 11.14 69 284538 2992 31409745
Food aversion 21.98 11.14 21 284586 330 31412407
Colorectal cancer 21.84 11.14 8 284599 4821 31407916
Ileus 21.68 11.14 67 284540 15102 31397635
Hepatojugular reflux 21.60 11.14 26 284581 538 31412199
Blood cholesterol abnormal 21.41 11.14 46 284561 1579 31411158
Epistaxis 21.40 11.14 346 284261 53361 31359376
Prostate cancer 21.33 11.14 225 284382 37376 31375361
Actinic elastosis 21.29 11.14 10 284597 41 31412696
Conjunctivitis 20.95 11.14 28 284579 8595 31404142
Blood pressure fluctuation 20.93 11.14 119 284488 22617 31390120
Herpes zoster 20.87 11.14 185 284422 31808 31380929
Albumin urine present 20.86 11.14 21 284586 353 31412384
Drug withdrawal syndrome 20.77 11.14 92 284515 18658 31394079
Genital candidiasis 20.68 11.14 11 284596 62 31412675
Bronchitis 20.64 11.14 235 284372 38482 31374255
Aplasia pure red cell 20.62 11.14 13 284594 5724 31407013
Large for dates baby 20.39 11.14 32 284575 858 31411879
Diffuse large B-cell lymphoma 20.05 11.14 29 284578 8612 31404125
Respiratory failure 20.02 11.14 727 283880 100722 31312015
Cytomegalovirus test positive 20.01 11.14 4 284603 3601 31409136
Arthropathy 19.99 11.14 130 284477 23921 31388816
Device related infection 19.91 11.14 77 284530 16222 31396515
Balanitis candida 19.87 11.14 13 284594 113 31412624
Abdominal pain upper 19.85 11.14 732 283875 63270 31349467
Renal oncocytoma 19.73 11.14 9 284598 34 31412703
Basilar artery thrombosis 19.72 11.14 17 284590 232 31412505
Rales 19.66 11.14 139 284468 8500 31404237
Therapy partial responder 19.58 11.14 18 284589 6544 31406193
Restlessness 19.55 11.14 126 284481 23235 31389502
Diabetic foetopathy 19.51 11.14 16 284591 203 31412534
Pneumonia aspiration 19.51 11.14 238 284369 38488 31374249
Body temperature decreased 19.46 11.14 176 284431 11594 31401143
Product commingling 19.40 11.14 8 284599 22 31412715
Hypoalbuminaemia 19.34 11.14 44 284563 10984 31401753
Respiratory arrest 19.33 11.14 147 284460 26110 31386627
Productive cough 19.31 11.14 200 284407 33340 31379397
Nipple inflammation 19.29 11.14 10 284597 53 31412684
Herbal interaction 19.27 11.14 20 284587 349 31412388
Premature baby 19.20 11.14 90 284517 17976 31394761
Abnormal behaviour 19.20 11.14 130 284477 23698 31389039
Metabolic syndrome 19.18 11.14 43 284564 1520 31411217
Headache 19.12 11.14 1405 283202 182247 31230490
Adrenal cyst 19.08 11.14 14 284593 149 31412588
Cystitis haemorrhagic 18.98 11.14 12 284595 5277 31407460
Left ventricular dysfunction 18.70 11.14 146 284461 9211 31403526
Cytomegalovirus chorioretinitis 18.62 11.14 4 284603 3424 31409313
Birt-Hogg-Dube syndrome 18.61 11.14 5 284602 0 31412737
Cardiotoxicity 18.61 11.14 11 284596 5016 31407721
Pernicious anaemia 18.53 11.14 11 284596 79 31412658
pH body fluid abnormal 18.49 11.14 7 284600 14 31412723
Mydriasis 18.36 11.14 19 284588 6533 31406204
Colitis 18.33 11.14 205 284402 33682 31379055
Pulmonary toxicity 18.23 11.14 13 284594 5364 31407373
Atrial enlargement 18.15 11.14 19 284588 335 31412402
Urine output increased 18.15 11.14 34 284573 1055 31411682
Glomerular filtration rate increased 18.06 11.14 16 284591 227 31412510
Echocardiogram abnormal 18.01 11.14 31 284576 899 31411838
Lymphopenia 17.95 11.14 67 284540 14262 31398475
Retroperitoneal fibrosis 17.95 11.14 18 284589 301 31412436
Autoimmune pancreatitis 17.95 11.14 18 284589 301 31412436
Plasmapheresis 17.86 11.14 18 284589 303 31412434
Brain natriuretic peptide abnormal 17.76 11.14 18 284589 305 31412432
Malnutrition 17.71 11.14 49 284558 11444 31401293
Tendonitis 17.71 11.14 31 284576 8527 31404210
Pericardial disease 17.69 11.14 20 284587 386 31412351
Sedation 17.60 11.14 99 284508 18866 31393871
Febrile bone marrow aplasia 17.56 11.14 27 284580 7819 31404918
Pneumonitis 17.56 11.14 183 284424 30469 31382268
Pain 17.53 11.14 1441 283166 185318 31227419
Mucosal dryness 17.52 11.14 35 284572 1140 31411597
Erythromelalgia 17.47 11.14 9 284598 47 31412690
Oxygen saturation decreased 17.44 11.14 323 284284 48792 31363945
Central obesity 17.42 11.14 22 284585 479 31412258
Neuropathy vitamin B12 deficiency 17.36 11.14 11 284596 90 31412647
Liver palpable 17.35 11.14 17 284590 276 31412461
Inflammation 17.34 11.14 144 284463 25097 31387640
Leukocytosis 17.30 11.14 287 284320 21827 31390910
Nasopharyngitis 17.22 11.14 434 284173 62811 31349926
Tremor 17.09 11.14 539 284068 75881 31336856
Hepatic enzyme decreased 17.02 11.14 9 284598 50 31412687
Kussmaul respiration 16.97 11.14 11 284596 94 31412643
Drug dose titration not performed 16.97 11.14 17 284590 284 31412453
Amylase increased 16.86 11.14 95 284512 5367 31407370
Leukoencephalopathy 16.76 11.14 7 284600 3895 31408842
Hyperventilation 16.73 11.14 55 284552 2446 31410291
Wheezing 16.70 11.14 225 284382 35761 31376976
Hepatic vein dilatation 16.70 11.14 15 284592 217 31412520
Hypogammaglobulinaemia 16.63 11.14 21 284586 6606 31406131
Lymphoma 16.60 11.14 47 284560 10896 31401841
High density lipoprotein decreased 16.55 11.14 64 284543 3086 31409651
Ischaemic cardiomyopathy 16.54 11.14 100 284507 5797 31406940
Palmar-plantar erythrodysaesthesia syndrome 16.53 11.14 77 284530 15406 31397331
Pulmonary tuberculosis 16.49 11.14 11 284596 4700 31408037
Acute lung injury 16.47 11.14 37 284570 1310 31411427
Blood creatinine increased 16.42 11.14 967 283640 88111 31324626
Prerenal failure 16.41 11.14 45 284562 1808 31410929
Bacteraemia 16.39 11.14 92 284515 17542 31395195
Klebsiella infection 16.38 11.14 28 284579 7775 31404962
Pulmonary embolism 16.35 11.14 584 284023 81062 31331675
Hypoglycaemic unconsciousness 16.34 11.14 27 284580 757 31411980
Blood phosphorus increased 16.32 11.14 10 284597 4472 31408265
Sopor 16.27 11.14 167 284440 11385 31401352
Product administered to patient of inappropriate age 16.22 11.14 3 284604 2854 31409883
Akathisia 16.19 11.14 25 284582 7228 31405509
Intercapillary glomerulosclerosis 16.12 11.14 8 284599 38 31412699
Product substitution issue 16.09 11.14 142 284465 9290 31403447
Bradycardia 16.07 11.14 769 283838 68558 31344179
Gastroenteritis 16.04 11.14 186 284421 13076 31399661
Pulmonary valve disease 16.01 11.14 17 284590 305 31412432
Intestinal perforation 15.93 11.14 32 284575 8357 31404380
Pancreatitis haemorrhagic 15.92 11.14 17 284590 307 31412430
Angioedema 15.92 11.14 405 284202 33213 31379524
Anion gap abnormal 15.81 11.14 12 284595 135 31412602
Rhabdomyolysis 15.75 11.14 710 283897 62871 31349866
Stenosis 15.75 11.14 34 284573 1171 31411566
Encephalitis toxic 15.75 11.14 16 284591 272 31412465
Scrotal cyst 15.71 11.14 5 284602 4 31412733
Atrioventricular block complete 15.69 11.14 131 284476 8434 31404303
Hypoglycaemic encephalopathy 15.65 11.14 16 284591 274 31412463
Alopecia 15.65 11.14 115 284492 20580 31392157
Pancreaticoduodenectomy 15.58 11.14 9 284598 61 31412676
Liver disorder 15.56 11.14 181 284426 29526 31383211
Product appearance confusion 15.43 11.14 7 284600 26 31412711
Pneumatosis intestinalis 15.40 11.14 7 284600 3704 31409033
Insulin C-peptide decreased 15.34 11.14 8 284599 43 31412694
Hypovolaemic shock 15.31 11.14 105 284502 6357 31406380
Crohn's disease 15.28 11.14 9 284598 4112 31408625
Malignant spinal cord compression 15.24 11.14 12 284595 143 31412594
Body mass index abnormal 15.24 11.14 12 284595 143 31412594
Hyperammonaemia 15.15 11.14 18 284589 5815 31406922
Leukaemoid reaction 15.09 11.14 10 284597 89 31412648
Product complaint 15.06 11.14 93 284514 5431 31407306
Fibrillary glomerulonephritis 15.05 11.14 8 284599 45 31412692
Enthesopathy 15.02 11.14 10 284597 4277 31408460
Poor venous access 15.00 11.14 9 284598 4071 31408666
Product solubility abnormal 14.97 11.14 20 284587 461 31412276
Pain in extremity 14.97 11.14 872 283735 115331 31297406
Choluria 14.91 11.14 12 284595 148 31412589
Drug-disease interaction 14.89 11.14 19 284588 418 31412319
Skinfold measurement 14.89 11.14 4 284603 0 31412737
Atrioventricular node dysfunction 14.89 11.14 4 284603 0 31412737
Blood insulin decreased 14.89 11.14 4 284603 0 31412737
Antipsychotic drug level increased 14.82 11.14 66 284541 3392 31409345
Anaphylactic reaction 14.74 11.14 182 284425 29371 31383366
Respiratory syncytial virus infection 14.73 11.14 8 284599 3823 31408914
Intercepted product preparation error 14.72 11.14 5 284602 3159 31409578
Haematocrit decreased 14.67 11.14 186 284421 29875 31382862
Escherichia infection 14.62 11.14 27 284580 7277 31405460
Adrenal adenoma 14.61 11.14 17 284590 339 31412398
Graft versus host disease in skin 14.60 11.14 7 284600 3590 31409147
Asthma 14.58 11.14 282 284325 42329 31370408
Tinnitus 14.54 11.14 86 284521 16189 31396548
Chronic obstructive pulmonary disease 14.53 11.14 302 284305 44864 31367873
Thrombosis 14.50 11.14 302 284305 44849 31367888
Anhedonia 14.47 11.14 28 284579 7414 31405323
Pulmonary alveolar haemorrhage 14.46 11.14 24 284583 6742 31405995
Coma acidotic 14.30 11.14 5 284602 7 31412730
Bacterial infection 14.28 11.14 69 284538 13670 31399067
Hypersensitivity 14.25 11.14 386 284221 55357 31357380
Peritonitis bacterial 14.22 11.14 19 284588 5833 31406904
Irritability 14.22 11.14 134 284473 22755 31389982
Cardiac discomfort 14.19 11.14 21 284586 534 31412203
Cytomegalovirus colitis 14.18 11.14 3 284604 2595 31410142
Therapeutic drug monitoring analysis not performed 14.06 11.14 20 284587 490 31412247
Atrioventricular block first degree 14.05 11.14 94 284513 5643 31407094
Upper respiratory tract infection 14.00 11.14 183 284424 29239 31383498
Torsade de pointes 14.00 11.14 25 284582 6825 31405912
Dyslipidaemia 13.95 11.14 102 284505 6304 31406433
Blood pressure systolic increased 13.90 11.14 249 284358 19221 31393516
Blood lactic acid decreased 13.88 11.14 8 284599 54 31412683
Bundle branch block left 13.87 11.14 91 284516 5427 31407310
Oedematous pancreatitis 13.87 11.14 19 284588 449 31412288
Small intestinal obstruction 13.80 11.14 68 284539 13404 31399333
Bradypnoea 13.78 11.14 3 284604 2544 31410193
Diabetic coma 13.76 11.14 26 284581 812 31411925
Cardiogenic shock 13.75 11.14 280 284327 22128 31390609
Dermatitis acneiform 13.73 11.14 19 284588 5748 31406989
Injection site mass 13.72 11.14 95 284512 5769 31406968
Tachypnoea 13.67 11.14 216 284391 16267 31396470
Chronic pigmented purpura 13.66 11.14 10 284597 106 31412631
Post-traumatic amnestic disorder 13.64 11.14 8 284599 56 31412681
Product prescribing error 13.60 11.14 250 284357 19392 31393345
Methaemoglobinaemia 13.56 11.14 5 284602 3001 31409736
Ejection fraction decreased 13.54 11.14 226 284381 17208 31395529
Mouth haemorrhage 13.52 11.14 15 284592 4997 31407740
Periarthritis calcarea 13.41 11.14 9 284598 82 31412655
Serotonin syndrome 13.40 11.14 106 284501 18667 31394070
Orbital oedema 13.38 11.14 11 284596 140 31412597
Staphylococcal sepsis 13.31 11.14 40 284567 9097 31403640
Oscillopsia 13.22 11.14 7 284600 39 31412698
Subdural hygroma 13.21 11.14 15 284592 291 31412446
Articular calcification 13.15 11.14 9 284598 85 31412652
Virologic failure 13.09 11.14 6 284601 3159 31409578
Diabetic vascular disorder 13.08 11.14 7 284600 40 31412697
Coma uraemic 13.08 11.14 7 284600 40 31412697
Brain oedema 13.01 11.14 65 284542 12767 31399970
Pseudomembranous colitis 13.00 11.14 4 284603 2691 31410046
Pneumonia bacterial 12.99 11.14 48 284559 10248 31402489
Rheumatoid nodule 12.89 11.14 4 284603 2677 31410060
Pyonephrosis 12.88 11.14 8 284599 63 31412674
Paradoxical drug reaction 12.83 11.14 6 284601 3123 31409614
Gingival hypertrophy 12.82 11.14 40 284567 1730 31411007
Multiple sclerosis relapse 12.81 11.14 60 284547 11987 31400750
Hemiparaesthesia 12.81 11.14 7 284600 42 31412695
Respiratory depression 12.79 11.14 77 284530 14433 31398304
Confusional state 12.79 11.14 1376 283231 131958 31280779
Cerebellar ischaemia 12.78 11.14 10 284597 118 31412619
Hypoaesthesia eye 12.70 11.14 6 284601 25 31412712
Back pain 12.70 11.14 829 283778 108584 31304153
Hepatobiliary scan abnormal 12.68 11.14 4 284603 3 31412734
Pancreatic duct obstruction 12.68 11.14 4 284603 3 31412734
Benign neoplasm of adrenal gland 12.68 11.14 4 284603 3 31412734
Blood lactate dehydrogenase increased 12.66 11.14 119 284488 20220 31392517
Blood alkaline phosphatase increased 12.66 11.14 187 284420 29266 31383471
Body temperature increased 12.61 11.14 82 284525 15091 31397646
Nipple disorder 12.59 11.14 12 284595 188 31412549
Ventricular enlargement 12.51 11.14 18 284589 446 31412291
Transaminases increased 12.48 11.14 149 284458 24192 31388545
Weight increased 12.48 11.14 885 283722 82062 31330675
Mitral valve incompetence 12.45 11.14 186 284421 13847 31398890
Bacterial sepsis 12.43 11.14 15 284592 4813 31407924
Lichenification 12.39 11.14 14 284593 270 31412467
Neonatal respiratory distress syndrome 12.39 11.14 10 284597 3875 31408862
Diabetic gangrene 12.39 11.14 12 284595 192 31412545
Bladder papilloma 12.35 11.14 6 284601 27 31412710
Vascular resistance systemic decreased 12.33 11.14 9 284598 95 31412642
Scoliosis 12.28 11.14 4 284603 2595 31410142
Emotional distress 12.23 11.14 77 284530 14279 31398458
Abnormal loss of weight 12.21 11.14 67 284540 3748 31408989
Blood bilirubin increased 12.19 11.14 232 284375 34904 31377833
Cryptococcosis 12.16 11.14 3 284604 2335 31410402
Cardiac septal hypertrophy 12.15 11.14 14 284593 276 31412461
Mouth ulceration 12.15 11.14 53 284554 10795 31401942
Leg amputation 12.14 11.14 44 284563 2056 31410681
Uveitis 12.11 11.14 27 284580 6789 31405948
Loss of consciousness 12.10 11.14 828 283779 76527 31336210
Finger amputation 12.09 11.14 11 284596 162 31412575
Lichen sclerosus 12.06 11.14 5 284602 14 31412723
Oliguria 12.05 11.14 114 284493 7603 31405134
Spondylolysis 12.00 11.14 8 284599 72 31412665
Transferrin saturation decreased 11.97 11.14 15 284592 324 31412413
Vitamin B1 decreased 11.96 11.14 14 284593 281 31412456
Myoclonus 11.94 11.14 75 284532 13915 31398822
Squamous cell carcinoma of skin 11.83 11.14 49 284558 10125 31402612
Hepatic neoplasm 11.82 11.14 41 284566 1874 31410863
Exercise tolerance decreased 11.82 11.14 77 284530 4581 31408156
Endometriosis male 11.81 11.14 5 284602 15 31412722
Renal aplasia 11.80 11.14 22 284585 680 31412057
Hypovolaemia 11.77 11.14 121 284486 8251 31404486
Asthenia 11.76 11.14 2239 282368 222516 31190221
Extrapyramidal disorder 11.75 11.14 60 284547 11718 31401019
Ischaemic stroke 11.75 11.14 216 284391 16755 31395982
Base excess decreased 11.72 11.14 12 284595 206 31412531
Skin cancer 11.68 11.14 44 284563 9341 31403396
Dermatosis 11.66 11.14 14 284593 289 31412448
Hepatic haematoma 11.65 11.14 16 284591 379 31412358
Eosinophilic colitis 11.63 11.14 12 284595 208 31412529
Viral infection 11.62 11.14 87 284520 15506 31397231
Fixed eruption 11.61 11.14 34 284573 1419 31411318
Red blood cell count decreased 11.59 11.14 170 284437 26637 31386100
Fistula 11.59 11.14 21 284586 5700 31407037
Alcoholic ketoacidosis 11.58 11.14 5 284602 16 31412721
Ankylosing spondylitis 11.54 11.14 22 284585 5859 31406878
Macular oedema 11.49 11.14 51 284556 2617 31410120
Blood albumin decreased 11.48 11.14 65 284542 12366 31400371
Urosepsis 11.45 11.14 158 284449 11562 31401175
Miosis 11.45 11.14 39 284568 8531 31404206
Diabetic complication 11.40 11.14 21 284586 643 31412094
Hemiplegia 11.36 11.14 101 284506 6621 31406116
Psychomotor skills impaired 11.35 11.14 7 284600 3120 31409617
Erythema 11.33 11.14 598 284009 79807 31332930
Hemianopia homonymous 11.30 11.14 22 284585 703 31412034
Dyspnoea at rest 11.29 11.14 62 284545 3469 31409268
Base excess negative 11.28 11.14 4 284603 6 31412731
Intraductal papillary-mucinous carcinoma of pancreas 11.28 11.14 4 284603 6 31412731
Hypoparathyroidism 11.26 11.14 19 284588 542 31412195
Lip oedema 11.23 11.14 46 284561 2278 31410459
Diabetic encephalopathy 11.17 11.14 3 284604 0 31412737
Thyroid calcification 11.17 11.14 3 284604 0 31412737
Benign neoplasm of testis 11.17 11.14 3 284604 0 31412737
Pure white cell aplasia 11.17 11.14 3 284604 0 31412737
Thyroid C-cell hyperplasia 11.17 11.14 3 284604 0 31412737
Base excess 11.17 11.14 3 284604 0 31412737
Pancreatic enzymes abnormal 11.17 11.14 3 284604 0 31412737
Genital tract inflammation 11.17 11.14 3 284604 0 31412737
Claudication of jaw muscles 11.17 11.14 3 284604 0 31412737
Dawn phenomenon 11.17 11.14 3 284604 0 31412737
Essential hypertension 11.15 11.14 50 284557 2577 31410160

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 23657.46 10.10 10894 514982 54130 70348438
Acute kidney injury 5793.41 10.10 11579 514297 463045 69939523
Hypoglycaemia 4763.91 10.10 4593 521283 89771 70312797
Metabolic acidosis 3991.56 10.10 3745 522131 70601 70331967
Diabetic ketoacidosis 3259.59 10.10 2327 523549 29185 70373383
Blood glucose increased 2269.20 10.10 3279 522597 99703 70302865
Hyperkalaemia 1704.02 10.10 2930 522946 103661 70298907
Euglycaemic diabetic ketoacidosis 1605.02 10.10 817 525059 5190 70397378
Diabetes mellitus inadequate control 1390.43 10.10 1231 524645 21414 70381154
Ketoacidosis 1353.43 10.10 778 525098 6491 70396077
Glycosylated haemoglobin increased 1313.40 10.10 1065 524811 16326 70386242
Hyperglycaemia 1174.12 10.10 1883 523993 62789 70339779
Rheumatoid arthritis 795.01 10.10 601 525275 291204 70111364
Shock 726.61 10.10 1172 524704 39253 70363315
Hyperlactacidaemia 724.65 10.10 458 525418 4614 70397954
Drug ineffective 713.69 10.10 4077 521799 935675 69466893
Hypoglycaemic coma 712.60 10.10 429 525447 3932 70398636
Pancreatitis acute 690.48 10.10 1219 524657 44005 70358563
Pancreatitis 625.18 10.10 1414 524462 61254 70341314
Off label use 588.53 10.10 3177 522699 739883 69662685
Pemphigoid 586.00 10.10 617 525259 13405 70389163
Systemic lupus erythematosus 567.52 10.10 51 525825 101851 70300717
Synovitis 512.36 10.10 160 525716 129068 70273500
Infusion related reaction 504.93 10.10 433 525443 197101 70205467
Renal failure 497.84 10.10 2737 523139 186333 70216235
Drug intolerance 485.23 10.10 575 525301 225112 70177456
Diabetic metabolic decompensation 480.07 10.10 293 525583 2759 70399809
Anuria 472.43 10.10 653 525223 19000 70383568
Diabetes mellitus 464.41 10.10 1377 524499 70447 70332121
Hand deformity 453.91 10.10 54 525822 86428 70316140
Blood lactic acid increased 453.34 10.10 484 525392 10689 70391879
Anti-cyclic citrullinated peptide antibody positive 448.90 10.10 16 525860 70169 70332399
Pemphigus 448.04 10.10 47 525829 82989 70319579
Blood glucose decreased 447.21 10.10 710 525166 23449 70379119
Glossodynia 425.48 10.10 66 525810 86421 70316147
Blood glucose abnormal 421.74 10.10 433 525443 9124 70393444
Arthropathy 414.77 10.10 304 525572 149753 70252815
Treatment failure 408.92 10.10 284 525592 143858 70258710
Joint swelling 385.88 10.10 812 525064 252399 70150169
Dehydration 359.90 10.10 2887 522989 223255 70179313
Toxicity to various agents 356.89 10.10 4365 521511 377807 70024761
Vomiting 349.76 10.10 6255 519621 586856 69815712
Vitamin B12 deficiency 345.45 10.10 314 525562 5658 70396910
Intentional overdose 344.18 10.10 1545 524331 96890 70305678
Pericarditis 340.89 10.10 102 525774 84603 70317965
Febrile neutropenia 339.95 10.10 622 525254 203696 70198872
Drug level increased 339.55 10.10 801 525075 35668 70366900
Diarrhoea 323.14 10.10 7837 518039 775504 69627064
Therapeutic product effect decreased 321.78 10.10 351 525525 142667 70259901
Completed suicide 315.50 10.10 2813 523063 224322 70178246
Haemodialysis 305.88 10.10 499 525377 16867 70385701
Pyrexia 304.07 10.10 2956 522920 603996 69798572
Duodenal ulcer perforation 303.21 10.10 19 525857 51093 70351475
Alopecia 298.56 10.10 641 525235 197849 70204719
Hypersensitivity 289.32 10.10 814 525062 228998 70173570
Rheumatoid factor positive 287.09 10.10 18 525858 48382 70354186
Rash 278.25 10.10 2434 523442 508128 69894440
Drug abuse 276.76 10.10 414 525462 146842 70255726
Hypothermia 273.73 10.10 523 525353 20071 70382497
Stomatitis 273.27 10.10 330 525546 128181 70274387
Blood glucose fluctuation 271.22 10.10 281 525595 5986 70396582
Helicobacter infection 270.28 10.10 44 525832 55612 70346956
Anion gap increased 266.41 10.10 208 525668 3008 70399560
Continuous haemodiafiltration 261.56 10.10 170 525706 1804 70400764
Arthralgia 255.95 10.10 2442 523434 500948 69901620
Acidosis 255.41 10.10 474 525402 17789 70384779
Pancreatic carcinoma 253.79 10.10 390 525486 12514 70390054
Neutropenia 253.74 10.10 1013 524863 256143 70146425
Folliculitis 252.00 10.10 16 525860 42554 70360014
Contraindicated product administered 247.62 10.10 384 525492 134228 70268340
Drug hypersensitivity 242.15 10.10 1061 524815 261398 70141170
Drug interaction 237.57 10.10 4060 521816 377381 70025187
Sleep disorder due to general medical condition, insomnia type 236.26 10.10 6 525870 35726 70366842
Wound 235.98 10.10 230 525646 98502 70304066
Swelling 232.70 10.10 674 525202 187865 70214703
Infection 231.03 10.10 795 525081 209990 70192578
Muscle injury 229.26 10.10 14 525862 38480 70364088
Hypomagnesaemia 217.04 10.10 731 525145 40033 70362535
Pain 211.26 10.10 3336 522540 625480 69777088
Irritable bowel syndrome 210.54 10.10 58 525818 50792 70351776
Product use issue 209.33 10.10 661 525215 179276 70223292
Product use in unapproved indication 209.26 10.10 810 525066 206668 70195900
Musculoskeletal stiffness 209.22 10.10 493 525383 147267 70255301
Blood bicarbonate decreased 203.92 10.10 216 525660 4725 70397843
Overdose 202.52 10.10 2036 523840 167709 70234859
Sinusitis 202.16 10.10 614 525262 168581 70233987
Maternal exposure during pregnancy 178.80 10.10 366 525510 114979 70287589
Weight decreased 176.84 10.10 3259 522617 307229 70095339
Discomfort 171.68 10.10 325 525551 105111 70297457
Ketonuria 171.36 10.10 107 525769 1053 70401515
Polyuria 169.06 10.10 333 525543 13073 70389495
Cytomegalovirus infection 163.38 10.10 46 525830 39712 70362856
Diabetic neuropathy 162.83 10.10 209 525667 5649 70396919
Rhabdomyolysis 159.48 10.10 1236 524640 94524 70308044
Suicide attempt 155.80 10.10 1067 524809 78443 70324125
Impaired healing 150.74 10.10 198 525678 74176 70328392
Ketosis 149.30 10.10 95 525781 969 70401599
Blood pH decreased 145.86 10.10 173 525703 4303 70398265
Hypotension 143.15 10.10 3968 521908 400413 70002155
C-reactive protein abnormal 142.06 10.10 54 525822 38525 70364043
MELAS syndrome 141.77 10.10 53 525823 133 70402435
Injection site nodule 140.28 10.10 148 525728 3222 70399346
Pneumonia 139.91 10.10 3360 522516 592872 69809696
Immune-mediated myositis 137.16 10.10 141 525735 2975 70399593
Blood creatinine increased 135.93 10.10 1640 524236 141361 70261207
Urine ketone body present 134.65 10.10 145 525731 3234 70399334
Myocardial infarction 134.08 10.10 1899 523977 169746 70232822
White blood cell count decreased 133.53 10.10 728 525148 169413 70233155
Type 2 diabetes mellitus 132.91 10.10 663 525213 43417 70359151
Hepatic enzyme increased 130.32 10.10 659 525217 156331 70246237
Drug resistance 130.10 10.10 60 525816 38130 70364438
Base excess decreased 128.01 10.10 60 525816 309 70402259
Thrombocytopenia 125.89 10.10 1149 524727 237961 70164607
Platelet count decreased 123.73 10.10 793 525083 177429 70225139
Renal impairment 119.93 10.10 1611 524265 142326 70260242
Plasma cell myeloma 118.83 10.10 226 525650 72975 70329593
Bone marrow failure 118.44 10.10 113 525763 48897 70353671
Acetonaemia 117.28 10.10 53 525823 247 70402321
Contusion 111.72 10.10 528 525348 127508 70275060
Condition aggravated 111.17 10.10 2371 523505 425264 69977304
Distributive shock 110.94 10.10 108 525768 2129 70400439
Anaemia vitamin B12 deficiency 110.06 10.10 66 525810 600 70401968
Glomerular filtration rate decreased 109.40 10.10 371 525505 20385 70382183
Tachypnoea 108.79 10.10 461 525415 28177 70374391
Abdominal discomfort 107.62 10.10 1044 524832 213614 70188954
Neurologic neglect syndrome 107.09 10.10 109 525767 2272 70400296
Ill-defined disorder 104.64 10.10 152 525724 54589 70347979
Renal tubular necrosis 104.05 10.10 393 525483 22778 70379790
Diabetic retinopathy 102.82 10.10 117 525759 2780 70399788
Nasopharyngitis 101.82 10.10 1104 524772 221102 70181466
Blood lactic acid 101.00 10.10 55 525821 408 70402160
Drug level above therapeutic 100.89 10.10 195 525681 7547 70395021
Seizure 99.45 10.10 842 525034 177120 70225448
Carotid artery thrombosis 99.26 10.10 108 525768 2438 70400130
Leukopenia 99.21 10.10 429 525447 106131 70296437
Pneumocystis jirovecii pneumonia 98.30 10.10 50 525826 30032 70372536
Bladder cancer 97.85 10.10 316 525560 16926 70385642
Hemiplegia 97.08 10.10 274 525602 13621 70388947
Hepatic steatosis 95.94 10.10 500 525376 33313 70369255
Hypocapnia 94.94 10.10 58 525818 547 70402021
Therapy non-responder 94.78 10.10 275 525601 76640 70325928
Haemodynamic instability 94.38 10.10 293 525583 15365 70387203
Graft versus host disease 94.09 10.10 4 525872 15019 70387549
Neutrophil count decreased 93.59 10.10 312 525564 83244 70319324
Blood ketone body increased 93.16 10.10 60 525816 626 70401942
Rheumatic fever 92.70 10.10 11 525865 17649 70384919
Intentional product use issue 92.08 10.10 518 525358 119624 70282944
Lipase increased 91.63 10.10 285 525591 14961 70387607
Death 91.13 10.10 2985 522891 507076 69895492
Hypovolaemia 90.66 10.10 293 525583 15700 70386868
Macroangiopathy 88.93 10.10 36 525840 120 70402448
Suspected suicide 88.78 10.10 200 525676 8634 70393934
Swollen joint count increased 88.02 10.10 3 525873 13697 70388871
Bradycardia 87.97 10.10 1355 524521 123260 70279308
Inflammation 87.92 10.10 294 525582 78371 70324197
Acute myocardial infarction 87.67 10.10 876 525000 72011 70330557
Microalbuminuria 87.43 10.10 64 525812 835 70401733
Transplant rejection 86.81 10.10 15 525861 18156 70384412
Diabetic nephropathy 86.78 10.10 105 525771 2668 70399900
Disease progression 86.75 10.10 743 525133 155929 70246639
Headache 86.46 10.10 3473 522403 576932 69825636
Insulin resistance 85.69 10.10 72 525804 1162 70401406
Posterior reversible encephalopathy syndrome 85.22 10.10 37 525839 24365 70378203
Personality disorder 85.22 10.10 150 525726 5398 70397170
Myelosuppression 84.62 10.10 60 525816 30085 70372483
Therapeutic product effect incomplete 83.38 10.10 533 525343 119349 70283219
Malignant neoplasm progression 82.77 10.10 545 525331 121194 70281374
Exposure via ingestion 82.21 10.10 138 525738 4777 70397791
Migraine 82.10 10.10 268 525608 71970 70330598
Product residue present 81.02 10.10 112 525764 3258 70399310
Exposure during pregnancy 80.52 10.10 355 525521 87362 70315206
Latent autoimmune diabetes in adults 79.52 10.10 29 525847 66 70402502
Anaemia megaloblastic 79.43 10.10 51 525825 529 70402039
Urine albumin/creatinine ratio abnormal 79.37 10.10 21 525855 3 70402565
Polydipsia 77.03 10.10 150 525726 5838 70396730
Cardiac arrest 76.16 10.10 1634 524242 158200 70244368
Glycosylated haemoglobin abnormal 74.55 10.10 33 525843 145 70402423
Blister 74.04 10.10 439 525437 100087 70302481
Mucosal inflammation 73.50 10.10 257 525619 67593 70334975
Hypoglycaemic encephalopathy 73.35 10.10 50 525826 578 70401990
Arthritis 73.16 10.10 426 525450 97554 70305014
Coma acidotic 73.01 10.10 30 525846 105 70402463
Angioedema 71.81 10.10 783 525093 65827 70336741
Mobility decreased 71.08 10.10 459 525417 102540 70300028
Aspergillus infection 70.99 10.10 22 525854 17846 70384722
Hip arthroplasty 70.90 10.10 62 525814 27978 70374590
Infective pulmonary exacerbation of cystic fibrosis 70.69 10.10 5 525871 12153 70390415
Adjustment disorder 70.41 10.10 101 525775 3043 70399525
Coronary artery disease 68.81 10.10 740 525136 61996 70340572
Peripheral swelling 68.75 10.10 1287 524589 235276 70167292
Haemophagocytic lymphohistiocytosis 68.07 10.10 30 525846 19582 70382986
Tenosynovitis 67.96 10.10 11 525865 13965 70388603
Pathogen resistance 67.93 10.10 9 525867 13270 70389298
Epstein-Barr virus infection 67.38 10.10 9 525867 13189 70389379
Fatigue 67.32 10.10 5232 520644 819087 69583481
Neurotoxicity 67.25 10.10 73 525803 29753 70372815
Bronchopulmonary aspergillosis 67.00 10.10 36 525840 20966 70381602
Blood potassium increased 66.74 10.10 388 525488 26938 70375630
Hyperglycaemic hyperosmolar nonketotic syndrome 66.65 10.10 76 525800 1810 70400758
Acute coronary syndrome 66.28 10.10 310 525566 19769 70382799
Product odour abnormal 65.92 10.10 62 525814 1169 70401399
Osteoporosis 64.62 10.10 169 525707 48738 70353830
Hypovolaemic shock 64.59 10.10 202 525674 10635 70391933
Cerebrovascular accident 64.31 10.10 1454 524422 142016 70260552
Progressive multifocal leukoencephalopathy 64.19 10.10 31 525845 19183 70383385
Product prescribing error 63.83 10.10 501 525375 38451 70364117
Postprandial hypoglycaemia 63.44 10.10 24 525852 63 70402505
Venoocclusive liver disease 63.23 10.10 4 525872 10674 70391894
Vasoplegia syndrome 62.92 10.10 96 525780 3060 70399508
Cholelithiasis 62.86 10.10 581 525295 46759 70355809
Thirst 62.12 10.10 244 525632 14405 70388163
Fibromyalgia 62.07 10.10 167 525709 47707 70354861
Myocardial ischaemia 61.99 10.10 348 525528 23852 70378716
Pancreatic carcinoma metastatic 60.51 10.10 105 525771 3735 70398833
Vitamin B12 decreased 60.17 10.10 91 525785 2878 70399690
Post transplant lymphoproliferative disorder 59.44 10.10 5 525871 10540 70392028
Cytokine release syndrome 59.43 10.10 65 525811 26402 70376166
Immune reconstitution inflammatory syndrome 59.33 10.10 12 525864 12978 70389590
Nausea 58.78 10.10 7193 518683 844895 69557673
Injection site erythema 58.29 10.10 310 525566 72614 70329954
Knee arthroplasty 58.24 10.10 103 525773 34198 70368370
Diabetic ketoacidotic hyperglycaemic coma 57.98 10.10 30 525846 198 70402370
Haematotoxicity 57.73 10.10 15 525861 13659 70388909
Oliguria 57.72 10.10 243 525633 14808 70387760
Abdominal pain 57.69 10.10 3095 522781 339032 70063536
Cytomegalovirus viraemia 57.26 10.10 9 525867 11676 70390892
Osmolar gap 57.23 10.10 26 525850 123 70402445
PCO2 decreased 56.57 10.10 89 525787 2915 70399653
Diabetic ketosis 56.35 10.10 36 525840 370 70402198
Bone erosion 56.26 10.10 21 525855 15152 70387416
Hepatic function abnormal 56.06 10.10 286 525590 67710 70334858
Rheumatoid nodule 55.62 10.10 21 525855 15046 70387522
Circulatory collapse 55.26 10.10 451 525425 35023 70367545
Cardiac failure 54.75 10.10 1423 524453 142118 70260450
Osteonecrosis 53.75 10.10 83 525793 29077 70373491
C-reactive protein increased 53.46 10.10 542 525334 109975 70292593
Clostridium difficile infection 52.93 10.10 132 525744 38684 70363884
Lower respiratory tract infection 52.84 10.10 552 525324 111361 70291207
Toxic epidermal necrolysis 52.03 10.10 137 525739 39420 70363148
Psoriatic arthropathy 51.96 10.10 275 525601 64496 70338072
Osmolar gap increased 51.71 10.10 17 525859 24 70402544
Eating disorder 51.61 10.10 273 525603 18292 70384276
Toe amputation 51.55 10.10 94 525782 3479 70399089
Adenocarcinoma pancreas 51.44 10.10 69 525807 1949 70400619
Glycosylated haemoglobin decreased 51.38 10.10 41 525835 613 70401955
Therapeutic response decreased 50.99 10.10 241 525635 58212 70344356
Pancreatitis chronic 50.70 10.10 96 525780 3658 70398910
Pancytopenia 50.68 10.10 801 525075 150306 70252262
Injection site reaction 50.59 10.10 194 525682 49658 70352910
Pregnancy 50.58 10.10 61 525815 23720 70378848
Dialysis 50.52 10.10 259 525617 17143 70385425
Glycosuria 49.90 10.10 70 525806 2065 70400503
Syncope 49.76 10.10 1594 524282 164115 70238453
Atrioventricular block 49.55 10.10 206 525670 12482 70390086
Angina pectoris 49.53 10.10 563 525313 47820 70354748
Genital infection fungal 49.46 10.10 25 525851 156 70402412
Anion gap 49.30 10.10 65 525811 1805 70400763
Accidental overdose 49.16 10.10 436 525440 34685 70367883
Sedation complication 48.99 10.10 19 525857 13391 70389177
Herpes zoster 48.61 10.10 401 525475 84834 70317734
Diabetic foot infection 48.53 10.10 42 525834 707 70401861
Glucose urine present 48.46 10.10 61 525815 1616 70400952
Amylase increased 48.22 10.10 176 525700 10032 70392536
Malaise 47.86 10.10 3778 522098 429154 69973414
Product monitoring error 47.71 10.10 134 525742 6642 70395926
Gastroenteritis 47.63 10.10 395 525481 30818 70371750
Cardiovascular disorder 47.63 10.10 247 525629 16423 70386145
Antipsychotic drug level decreased 47.54 10.10 49 525827 1037 70401531
Bursitis 47.21 10.10 78 525798 26595 70375973
Affect lability 47.15 10.10 174 525702 9972 70392596
Red blood cell sedimentation rate increased 46.99 10.10 139 525737 38503 70364065
Anhidrosis 46.97 10.10 26 525850 200 70402368
Sopor 46.82 10.10 394 525482 30873 70371695
Flushing 46.67 10.10 387 525489 81785 70320783
Multiple sclerosis relapse 46.55 10.10 163 525713 42854 70359714
Hypophagia 46.35 10.10 492 525384 41078 70361490
Hospitalisation 45.93 10.10 391 525485 82177 70320391
Needle issue 45.63 10.10 181 525695 10734 70391834
Naevus flammeus 45.50 10.10 19 525857 70 70402498
Device expulsion 45.29 10.10 59 525817 22187 70380381
Blindness transient 45.21 10.10 101 525775 4335 70398233
Kussmaul respiration 44.30 10.10 31 525845 375 70402193
Osteoarthritis 44.04 10.10 345 525531 73802 70328766
Enthesopathy 43.87 10.10 13 525863 10856 70391712
Colitis ulcerative 43.47 10.10 119 525757 33804 70368764
Drug dependence 43.42 10.10 137 525739 37184 70365384
High density lipoprotein decreased 43.36 10.10 95 525781 4024 70398544
Pain in jaw 43.33 10.10 166 525710 42503 70360065
Neuropathy peripheral 43.11 10.10 671 525205 126225 70276343
Blood ketone body 43.05 10.10 21 525855 120 70402448
Asthenia 42.60 10.10 3943 521933 453723 69948845
Loss of personal independence in daily activities 42.49 10.10 413 525463 84497 70318071
Thrombotic microangiopathy 42.14 10.10 42 525834 17806 70384762
Acute myeloid leukaemia 41.58 10.10 106 525770 30834 70371734
Prerenal failure 41.36 10.10 83 525793 3303 70399265
Lymphocyte count decreased 41.30 10.10 174 525702 43365 70359203
Insulin C-peptide decreased 41.27 10.10 17 525859 60 70402508
Stevens-Johnson syndrome 40.94 10.10 133 525743 35774 70366794
Pulmonary arterial hypertension 40.81 10.10 117 525759 32738 70369830
Urinary tract discomfort 40.77 10.10 31 525845 430 70402138
Pollakiuria 40.63 10.10 403 525473 33058 70369510
Base excess negative 40.54 10.10 13 525863 16 70402552
Disability 40.53 10.10 31 525845 14952 70387616
Haematuria 39.88 10.10 678 525198 62895 70339673
Bladder transitional cell carcinoma 39.85 10.10 69 525807 2450 70400118
Foot deformity 39.82 10.10 57 525819 20598 70381970
Staphylococcal infection 39.43 10.10 233 525643 53171 70349397
Pancreatic neoplasm 39.35 10.10 51 525825 1392 70401176
Depression 39.17 10.10 1149 524727 197825 70204743
Bradyarrhythmia 39.17 10.10 89 525787 3864 70398704
Blood triglycerides increased 39.16 10.10 265 525611 19399 70383169
Sedation 38.84 10.10 196 525680 46535 70356033
Basilar artery thrombosis 38.79 10.10 28 525848 357 70402211
Unintentional medical device removal 38.50 10.10 4 525872 7120 70395448
Joint range of motion decreased 38.29 10.10 85 525791 25941 70376627
Balanoposthitis 38.09 10.10 40 525836 866 70401702
Adverse event 38.02 10.10 213 525663 49248 70353320
Clostridium difficile colitis 37.70 10.10 101 525775 28895 70373673
Osteonecrosis of jaw 37.58 10.10 166 525710 40836 70361732
Medication error 37.55 10.10 612 525264 56300 70346268
Dystonia 37.38 10.10 55 525821 19651 70382917
Drug reaction with eosinophilia and systemic symptoms 37.28 10.10 264 525612 57749 70344819
Oral herpes 37.24 10.10 77 525799 24109 70378459
Myopathy 37.17 10.10 251 525625 18361 70384207
Metabolic syndrome 36.83 10.10 66 525810 2409 70400159
Mouth ulceration 36.60 10.10 131 525745 34218 70368350
Hypoglycaemic unconsciousness 36.43 10.10 44 525832 1116 70401452
Interstitial lung disease 36.42 10.10 551 525325 104134 70298434
Coma 36.33 10.10 915 524961 90929 70311639
Status epilepticus 36.16 10.10 80 525796 24446 70378122
Cytomegalovirus infection reactivation 36.15 10.10 4 525872 6777 70395791
Body temperature decreased 35.63 10.10 347 525529 28325 70374243
Pleural effusion 35.48 10.10 733 525143 132131 70270437
Dyslipidaemia 35.36 10.10 156 525720 9704 70392864
Multiple-drug resistance 35.29 10.10 6 525870 7349 70395219
Tubulointerstitial nephritis 34.81 10.10 387 525489 32689 70369879
Product substitution issue 34.80 10.10 246 525630 18267 70384301
Confusional state 34.76 10.10 2502 523374 281896 70120672
Immunosuppressant drug level increased 34.69 10.10 8 525868 7899 70394669
Grip strength decreased 34.69 10.10 39 525837 15646 70386922
Chronic sinusitis 34.31 10.10 10 525866 8441 70394127
Urine ketone body 34.18 10.10 20 525856 173 70402395
Facet joint syndrome 34.18 10.10 3 525873 6110 70396458
Diabetic foot 34.00 10.10 74 525802 3120 70399448
Nephrogenic systemic fibrosis 33.76 10.10 3 525873 6049 70396519
Hyponatraemia 33.61 10.10 1480 524396 158607 70243961
Lymphopenia 33.56 10.10 98 525778 27261 70375307
Blood calcium decreased 33.48 10.10 106 525770 28740 70373828
Leukocytosis 33.42 10.10 445 525431 39223 70363345
Drug ineffective for unapproved indication 32.96 10.10 160 525716 38378 70364190
Complications of transplanted kidney 32.94 10.10 3 525873 5931 70396637
Multiple sclerosis 32.93 10.10 88 525788 25197 70377371
No adverse event 32.70 10.10 125 525751 32028 70370540
Alveolar osteitis 32.44 10.10 30 525846 553 70402015
Electrocardiogram T wave peaked 32.18 10.10 36 525840 839 70401729
Neuropathy vitamin B12 deficiency 32.13 10.10 12 525864 30 70402538
Myelodysplastic syndrome 32.13 10.10 113 525763 29672 70372896
5-hydroxyindolacetic acid in urine increased 32.06 10.10 21 525855 226 70402342
Hypoaesthesia 31.97 10.10 881 524995 152858 70249710
Liver disorder 31.85 10.10 297 525579 61271 70341297
Alanine aminotransferase increased 31.75 10.10 841 525035 146639 70255929
Aspartate aminotransferase increased 31.74 10.10 708 525168 126270 70276298
Blood mercury abnormal 31.60 10.10 20 525856 202 70402366
Anxiety 31.47 10.10 1324 524552 219006 70183562
Pneumothorax 31.40 10.10 93 525783 25753 70376815
Dysarthria 31.26 10.10 642 525234 61671 70340897
Hemiparesis 31.23 10.10 364 525512 31105 70371463
Atrioventricular block complete 31.19 10.10 206 525670 14957 70387611
Ascites 31.13 10.10 335 525541 67212 70335356
Oedematous pancreatitis 31.12 10.10 38 525838 975 70401593
Coma scale abnormal 31.09 10.10 131 525745 7985 70394583
Coordination abnormal 31.09 10.10 215 525661 15851 70386717
Colorectal cancer 30.94 10.10 12 525864 8458 70394110
Decreased appetite 30.80 10.10 2642 523234 302138 70100430
Aphasia 30.39 10.10 470 525406 42779 70359789
Device related infection 30.29 10.10 129 525747 32056 70370512
Antipsychotic drug level increased 30.23 10.10 99 525777 5341 70397227
Choreoathetosis 30.06 10.10 46 525830 1470 70401098
Blood cholesterol increased 29.94 10.10 320 525556 64284 70338284
Ischaemic stroke 29.92 10.10 355 525521 30465 70372103
Hyperventilation 29.91 10.10 119 525757 7067 70395501
Allergic reaction to excipient 29.87 10.10 22 525854 290 70402278
Drug tolerance decreased 29.73 10.10 18 525858 9815 70392753
Lip dry 29.46 10.10 18 525858 9767 70392801
Aggression 29.43 10.10 224 525652 48222 70354346
Lung disorder 29.13 10.10 352 525524 69132 70333436
Peritonitis 29.06 10.10 98 525778 26061 70376507
Joint stiffness 28.96 10.10 148 525728 35028 70367540
Obstructive pancreatitis 28.94 10.10 31 525845 687 70401881
Atrial fibrillation 28.92 10.10 1657 524219 182691 70219877
Lumbosacral radiculoplexus neuropathy 28.87 10.10 13 525863 60 70402508
Tumour lysis syndrome 28.84 10.10 73 525803 21287 70381281
Hypocalcaemia 28.71 10.10 480 525396 44379 70358189
Pulseless electrical activity 28.69 10.10 182 525694 13033 70389535
Insulin-like growth factor increased 28.66 10.10 49 525827 1722 70400846
Aplastic anaemia 28.55 10.10 50 525826 16666 70385902
Type V hyperlipidaemia 28.53 10.10 36 525840 956 70401612
Enterococcal infection 28.35 10.10 40 525836 14542 70388026
Dry eye 28.21 10.10 133 525743 32149 70370419
Wrong patient received product 28.09 10.10 85 525791 4395 70398173
Low density lipoprotein abnormal 28.06 10.10 23 525853 358 70402210
Conjunctivitis 27.83 10.10 81 525795 22555 70380013
Immunodeficiency 27.78 10.10 55 525821 17500 70385068
Basal cell carcinoma 27.62 10.10 142 525734 33556 70369012
Cerebral venous thrombosis 27.61 10.10 59 525817 2456 70400112
Neoplasm progression 27.53 10.10 209 525667 45019 70357549
Neoplasm malignant 27.28 10.10 115 525761 28659 70373909
Blood insulin decreased 27.26 10.10 9 525867 13 70402555
Musculoskeletal disorder 27.16 10.10 68 525808 19903 70382665
Blood creatine phosphokinase increased 27.15 10.10 620 525256 60643 70341925
Pulmonary toxicity 27.15 10.10 24 525852 10774 70391794
Device use error 27.04 10.10 8 525868 6688 70395880
Constipation 26.88 10.10 1564 524312 250874 70151694
Polymyalgia rheumatica 26.53 10.10 76 525800 3810 70398758
Anovulatory cycle 26.51 10.10 15 525861 121 70402447
Acquired phimosis 26.45 10.10 11 525865 40 70402528
Starvation ketoacidosis 26.40 10.10 15 525861 122 70402446
Tongue oedema 26.33 10.10 104 525772 6155 70396413
Rales 26.23 10.10 217 525659 16918 70385650
Lupus-like syndrome 26.16 10.10 28 525848 11487 70391081
Glomerular filtration rate abnormal 26.15 10.10 43 525833 1463 70401105
Cytomegalovirus chorioretinitis 26.14 10.10 4 525872 5294 70397274
Unevaluable event 26.14 10.10 253 525623 51810 70350758
Respiratory syncytial virus infection 26.11 10.10 12 525864 7643 70394925
Pulmonary haemorrhage 26.09 10.10 38 525838 13635 70388933
Tinnitus 26.09 10.10 159 525717 36017 70366551
Body mass index increased 26.05 10.10 47 525829 1725 70400843
Drug use disorder 25.96 10.10 14 525862 8137 70394431
Bone density decreased 25.96 10.10 28 525848 11446 70391122
Cytopenia 25.96 10.10 56 525820 17267 70385301
Complication associated with device 25.94 10.10 48 525828 15665 70386903
Hypervolaemia 25.85 10.10 180 525696 39526 70363042
Vitreous haemorrhage 25.54 10.10 69 525807 3343 70399225
Obesity 25.39 10.10 307 525569 26464 70376104
Diffuse large B-cell lymphoma 25.35 10.10 37 525839 13265 70389303
Insomnia 25.29 10.10 1338 524538 216468 70186100
Pernicious anaemia 25.27 10.10 26 525850 549 70402019
Pancreatic pseudocyst 25.22 10.10 39 525837 1258 70401310
Generalised tonic-clonic seizure 25.13 10.10 193 525683 41468 70361100
Erythema 25.08 10.10 1216 524660 198347 70204221
Ulcer 25.00 10.10 102 525774 25652 70376916
Adrenal adenoma 24.96 10.10 36 525840 1090 70401478
Hypertensive crisis 24.86 10.10 235 525641 19027 70383541
Hypoparathyroidism 24.83 10.10 34 525842 980 70401588
Apolipoprotein A-I decreased 24.82 10.10 9 525867 20 70402548
Intestinal perforation 24.77 10.10 51 525825 15993 70386575
Motor dysfunction 24.76 10.10 174 525702 12896 70389672
Hypoxia 24.61 10.10 516 525360 92828 70309740
Enterocolitis 24.27 10.10 37 525839 13029 70389539
Graft versus host disease in skin 24.11 10.10 6 525870 5624 70396944
Serotonin syndrome 24.06 10.10 198 525678 41916 70360652
Pseudomonas infection 24.06 10.10 67 525809 18927 70383641
Dysuria 24.03 10.10 475 525401 45319 70357249
Sensory loss 24.01 10.10 156 525720 11263 70391305
Erythromelalgia 23.98 10.10 16 525860 178 70402390
Cardiotoxicity 23.97 10.10 28 525848 11042 70391526
Blood pressure fluctuation 23.96 10.10 301 525575 58711 70343857
Hepatojugular reflux 23.93 10.10 26 525850 586 70401982
Tunnel vision 23.92 10.10 37 525839 1194 70401374
Dizziness 23.87 10.10 3853 522023 460288 69942280
Incorrect route of product administration 23.83 10.10 108 525768 26384 70376184
Haemoptysis 23.78 10.10 255 525621 51197 70351371
Haemofiltration 23.73 10.10 12 525864 75 70402493
Blood pressure systolic increased 23.70 10.10 574 525302 56685 70345883
Bundle branch block left 23.69 10.10 145 525731 10254 70392314
Cold sweat 23.69 10.10 211 525665 16805 70385763
Blood chloride decreased 23.60 10.10 118 525758 7732 70394836
Ankylosing spondylitis 23.59 10.10 31 525845 11615 70390953
Hypoglycaemic seizure 23.48 10.10 29 525847 753 70401815
Cytomegalovirus test positive 23.33 10.10 6 525870 5502 70397066
Adrenal cyst 23.33 10.10 15 525861 156 70402412
Cholestatic liver injury 23.30 10.10 76 525800 4092 70398476
Device dislocation 23.21 10.10 87 525789 22420 70380148
Erectile dysfunction 23.09 10.10 176 525700 13386 70389182
Anion gap abnormal 22.98 10.10 24 525852 516 70402052
Actinic elastosis 22.94 10.10 10 525866 42 70402526
Central obesity 22.91 10.10 42 525834 1561 70401007
Ileus 22.90 10.10 97 525779 24140 70378428
Non-alcoholic steatohepatitis 22.77 10.10 48 525828 1979 70400589
Abnormal loss of weight 22.70 10.10 116 525760 7668 70394900
Left ventricular dysfunction 22.64 10.10 218 525658 17739 70384829
Chills 22.61 10.10 861 525015 143925 70258643
Retroperitoneal fibrosis 22.50 10.10 25 525851 578 70401990
Oxygen saturation decreased 22.48 10.10 674 525202 115755 70286813
Loss of consciousness 22.40 10.10 1389 524487 154327 70248241
Temperature perception test abnormal 22.31 10.10 8 525868 17 70402551
Food aversion 22.26 10.10 28 525848 741 70401827
Balanitis candida 22.26 10.10 13 525863 112 70402456
Gastrointestinal disorder 22.21 10.10 603 525273 104824 70297744
PO2 increased 22.19 10.10 40 525836 1467 70401101
Injection site warmth 22.15 10.10 43 525833 13782 70388786
Swollen tongue 22.12 10.10 392 525484 36654 70365914
Hypogammaglobulinaemia 22.08 10.10 32 525844 11506 70391062
Panniculitis 22.06 10.10 28 525848 10648 70391920
Cardiogenic shock 21.97 10.10 385 525491 35922 70366646
Granuloma skin 21.94 10.10 15 525861 7667 70394901
Macular oedema 21.90 10.10 86 525790 5076 70397492
Parkinsonism 21.83 10.10 191 525685 15134 70387434
Joint dislocation 21.75 10.10 47 525829 14484 70388084
Aplasia pure red cell 21.60 10.10 14 525862 7360 70395208
Joint effusion 21.60 10.10 52 525824 15425 70387143
Nipple inflammation 21.57 10.10 10 525866 50 70402518
Burkholderia pseudomallei infection 21.57 10.10 10 525866 50 70402518
Liver palpable 21.42 10.10 19 525857 331 70402237
Vitamin B1 deficiency 21.42 10.10 25 525851 611 70401957
Unresponsive to stimuli 21.31 10.10 520 525356 51411 70351157
Febrile bone marrow aplasia 21.28 10.10 35 525841 11956 70390612
Appendicitis 21.21 10.10 59 525817 16674 70385894
Substance abuse 21.17 10.10 25 525851 9812 70392756
Transferrin saturation decreased 21.08 10.10 30 525846 897 70401671
Haemorrhage 21.03 10.10 467 525409 83348 70319220
Device issue 20.98 10.10 99 525777 23926 70378642
Pain in extremity 20.94 10.10 2121 523755 325961 70076607
Dysentery 20.91 10.10 31 525845 963 70401605
Retinitis 20.85 10.10 3 525873 4157 70398411
Urine output increased 20.85 10.10 45 525831 1886 70400682
Bladder pain 20.84 10.10 46 525830 1958 70400610
Night sweats 20.80 10.10 215 525661 43469 70359099
Brain oedema 20.75 10.10 96 525780 23322 70379246
Body temperature increased 20.67 10.10 192 525684 39642 70362926
Postmenopausal haemorrhage 20.56 10.10 38 525838 1421 70401147
Bacteraemia 20.52 10.10 130 525746 29179 70373389
Cutaneous vasculitis 20.51 10.10 107 525769 7131 70395437
Pulmonary valve disease 20.46 10.10 17 525859 270 70402298
IIIrd nerve paresis 20.45 10.10 14 525862 163 70402405
Mydriasis 20.45 10.10 57 525819 16096 70386472
Blood parathyroid hormone decreased 20.44 10.10 22 525854 9002 70393566
Cleft lip 20.44 10.10 6 525870 4 70402564
Resuscitation 20.32 10.10 50 525826 2287 70400281
Injection site bruising 20.30 10.10 182 525694 37850 70364718
Pneumonia aspiration 20.26 10.10 332 525544 61957 70340611
Wheezing 20.26 10.10 537 525339 93633 70308935
Pulmonary tuberculosis 20.26 10.10 17 525859 7828 70394740
Deformity 20.20 10.10 19 525857 8278 70394290
Back pain 20.15 10.10 1733 524143 269419 70133149
Neuropathic arthropathy 20.14 10.10 18 525858 317 70402251
Femur fracture 20.13 10.10 171 525705 35961 70366607
Ischaemic cardiomyopathy 20.11 10.10 105 525771 6999 70395569
Arrhythmia 20.08 10.10 552 525324 55591 70346977
Suicidal ideation 20.07 10.10 379 525497 69217 70333351
Anaphylactic reaction 19.90 10.10 414 525462 74560 70328008
Infusion site erythema 19.86 10.10 16 525860 7519 70395049
Pelvic fracture 19.86 10.10 33 525843 11228 70391340
Nipple disorder 19.83 10.10 14 525862 172 70402396
Therapy partial responder 19.81 10.10 39 525837 12435 70390133
Respiratory arrest 19.75 10.10 281 525595 53652 70348916
Diabetic ulcer 19.73 10.10 16 525860 245 70402323
Birt-Hogg-Dube syndrome 19.56 10.10 5 525871 0 70402568
Granuloma 19.47 10.10 17 525859 7678 70394890
Rhinovirus infection 19.43 10.10 13 525863 6720 70395848
Exercise tolerance decreased 19.42 10.10 116 525760 8132 70394436
Hyperlipasaemia 19.40 10.10 31 525845 1029 70401539
Hallucination 19.39 10.10 424 525452 75836 70326732
Diabetes mellitus management 19.36 10.10 6 525870 6 70402562
Diabetic coma 19.30 10.10 33 525843 1160 70401408
Hyperinsulinaemia 19.23 10.10 14 525862 181 70402387
Product quality issue 19.19 10.10 326 525550 30235 70372333
Product administered to patient of inappropriate age 19.17 10.10 6 525870 4837 70397731
Poisoning 19.15 10.10 254 525622 22368 70380200
Foreign body aspiration 19.08 10.10 17 525859 298 70402270
Albuminuria 19.06 10.10 24 525852 636 70401932
Hyperinsulinaemic hypoglycaemia 19.02 10.10 13 525863 151 70402417
Venoocclusive disease 18.93 10.10 4 525872 4196 70398372
Pneumatosis intestinalis 18.91 10.10 10 525866 5877 70396691
Multiple organ dysfunction syndrome 18.90 10.10 985 524891 107530 70295038
Microcytic anaemia 18.89 10.10 78 525798 4711 70397857
Throat irritation 18.82 10.10 169 525707 35135 70367433
Methaemoglobinaemia 18.82 10.10 6 525870 4780 70397788
Renal oncocytoma 18.73 10.10 10 525866 71 70402497
Sepsis 18.61 10.10 1560 524316 242985 70159583
Albumin urine present 18.57 10.10 24 525852 653 70401915
Duodenal ulcer 18.53 10.10 184 525692 15096 70387472
Atrioventricular block first degree 18.50 10.10 149 525727 11524 70391044
Herbal interaction 18.43 10.10 20 525856 450 70402118
Renal artery thrombosis 18.43 10.10 20 525856 450 70402118
Malabsorption 18.38 10.10 76 525800 4594 70397974
Necrotising myositis 18.34 10.10 30 525846 1016 70401552
Injection site swelling 18.33 10.10 218 525658 42939 70359629
Hepatic vein dilatation 18.32 10.10 15 525861 233 70402335
Cystitis haemorrhagic 18.32 10.10 22 525854 8571 70393997
Deep vein thrombosis 18.31 10.10 656 525220 110386 70292182
Vitamin B1 decreased 18.24 10.10 18 525858 361 70402207
Overweight 18.17 10.10 63 525813 3500 70399068
Drug withdrawal syndrome 18.15 10.10 155 525721 32560 70370008
Necrotising fasciitis 18.01 10.10 85 525791 5441 70397127
Malignant mediastinal neoplasm 17.99 10.10 27 525849 848 70401720
Synovial cyst 17.99 10.10 23 525853 8719 70393849
Muscular weakness 17.91 10.10 1223 524653 137113 70265455
Diabetic hyperosmolar coma 17.91 10.10 25 525851 734 70401834
Large intestine perforation 17.89 10.10 45 525831 13150 70389418
Urosepsis 17.88 10.10 263 525613 23686 70378882
Diabetic complication 17.84 10.10 32 525844 1169 70401399
Glomerular filtration rate increased 17.79 10.10 22 525854 572 70401996
Gangrene 17.77 10.10 114 525762 8195 70394373
Ear infection 17.70 10.10 130 525746 28206 70374362
Liver function test increased 17.62 10.10 163 525713 33684 70368884
Labelled drug-disease interaction medication error 17.61 10.10 16 525860 288 70402280
Prothrombin consumption time prolonged 17.58 10.10 8 525868 38 70402530
Hepatic neoplasm 17.57 10.10 58 525818 3142 70399426
Drug-disease interaction 17.57 10.10 27 525849 866 70401702
Atelectasis 17.55 10.10 134 525742 28828 70373740
Brain stem infarction 17.54 10.10 41 525835 1814 70400754
Neuroendocrine tumour 17.46 10.10 34 525842 1323 70401245
Neutropenic sepsis 17.45 10.10 110 525766 24720 70377848
Intercapillary glomerulosclerosis 17.44 10.10 9 525867 59 70402509
Leukoencephalopathy 17.41 10.10 17 525859 7277 70395291
Coeliac disease 17.34 10.10 25 525851 9008 70393560
Malignant spinal cord compression 17.30 10.10 12 525864 143 70402425
Tongue disorder 17.25 10.10 46 525830 13181 70389387
Scrotal cyst 17.23 10.10 5 525871 3 70402565
Epistaxis 17.21 10.10 605 525271 102022 70300546
Cytomegalovirus colitis 17.16 10.10 5 525871 4221 70398347
Adjustment disorder with depressed mood 17.14 10.10 5 525871 4218 70398350
Blood growth hormone abnormal 17.10 10.10 8 525868 41 70402527
Herpes simplex 17.09 10.10 36 525840 11196 70391372
Hyperoxaluria 17.08 10.10 16 525860 300 70402268
Psoriasis 17.05 10.10 893 524983 97540 70305028
Thrombosis 17.01 10.10 427 525449 74978 70327590
Hormone receptor positive HER2 negative breast cancer 16.98 10.10 11 525865 116 70402452
Disseminated intravascular coagulation 16.98 10.10 163 525713 33435 70369133
Azotaemia 16.97 10.10 107 525769 7646 70394922
CD30 expression 16.95 10.10 8 525868 42 70402526
Mitochondrial enzyme deficiency 16.93 10.10 7 525869 25 70402543
Blindness cortical 16.90 10.10 27 525849 896 70401672
Drug level below therapeutic 16.88 10.10 24 525852 8699 70393869
Pneumonia viral 16.87 10.10 22 525854 8270 70394298
Decreased bronchial secretion 16.84 10.10 9 525867 64 70402504
Cerebellar ischaemia 16.82 10.10 12 525864 150 70402418
Injection site mass 16.81 10.10 209 525667 18134 70384434
Upper respiratory tract infection 16.80 10.10 453 525423 78821 70323747
Product appearance confusion 16.79 10.10 8 525868 43 70402525
Drug specific antibody present 16.78 10.10 11 525865 5747 70396821
Angina unstable 16.74 10.10 186 525690 15707 70386861
Virologic failure 16.68 10.10 4 525872 3846 70398722
Body mass index abnormal 16.66 10.10 14 525862 226 70402342
Peripheral sensory neuropathy 16.65 10.10 41 525835 12069 70390499
Low density lipoprotein decreased 16.65 10.10 30 525846 1100 70401468
Pleural fibrosis 16.62 10.10 5 525871 4134 70398434
Oedema 16.61 10.10 614 525262 102967 70299601
Anaemia macrocytic 16.58 10.10 79 525797 5076 70397492
Fear of injection 16.57 10.10 15 525861 6657 70395911
Respiratory tract infection 16.57 10.10 218 525658 42180 70360388
Blindness 16.54 10.10 253 525623 22974 70379594
Fibrillary glomerulonephritis 16.50 10.10 8 525868 45 70402523
Drug half-life increased 16.49 10.10 12 525864 155 70402413
Hyperhidrosis 16.45 10.10 1160 524716 130426 70272142
Diabetic gangrene 16.37 10.10 12 525864 157 70402411
Medullary thyroid cancer 16.37 10.10 12 525864 157 70402411
Renal abscess 16.35 10.10 27 525849 922 70401646
Red blood cell count decreased 16.32 10.10 280 525596 51881 70350687
Viral infection 16.27 10.10 194 525682 38197 70364371
Fixed eruption 16.26 10.10 48 525828 2448 70400120
Transfusion 16.23 10.10 78 525798 18758 70383810
Encephalitis toxic 16.16 10.10 15 525861 278 70402290
Treatment noncompliance 16.11 10.10 456 525420 46118 70356450
Pericardial disease 16.09 10.10 20 525856 523 70402045
Neuropathy, ataxia, retinitis pigmentosa syndrome 16.08 10.10 8 525868 48 70402520
Bundle branch block right 16.04 10.10 134 525742 10476 70392092
Prostatitis 16.01 10.10 64 525812 3809 70398759
Pancreatic mass 15.92 10.10 34 525842 1415 70401153
Lymphadenopathy 15.89 10.10 260 525616 48531 70354037
Flatulence 15.87 10.10 383 525493 37798 70364770
Clostridium test positive 15.86 10.10 8 525868 4828 70397740
Bacterial infection 15.85 10.10 123 525753 26369 70376199
Akathisia 15.84 10.10 43 525833 12250 70390318
Helicobacter gastritis 15.83 10.10 46 525830 2325 70400243
Parainfluenzae virus infection 15.78 10.10 9 525867 5071 70397497
Intestinal obstruction 15.77 10.10 198 525678 38627 70363941
Purpura 15.74 10.10 74 525802 17901 70384667
Pancreatitis haemorrhagic 15.69 10.10 23 525853 707 70401861
Myoglobin blood increased 15.65 10.10 54 525822 2993 70399575
Atrioventricular node dysfunction 15.65 10.10 4 525872 0 70402568
Pancreatic enzymes abnormal 15.65 10.10 4 525872 0 70402568
Peripheral venous disease 15.64 10.10 35 525841 10652 70391916
Expired product administered 15.62 10.10 91 525785 6322 70396246
Intestinal stenosis 15.61 10.10 3 525873 3364 70399204
Colitis 15.60 10.10 357 525519 63457 70339111
Mechanical ventilation complication 15.60 10.10 7 525869 32 70402536
Cholecystitis chronic 15.58 10.10 121 525755 9255 70393313
Post-traumatic amnestic disorder 15.56 10.10 8 525868 52 70402516
Uveitis 15.56 10.10 57 525819 14788 70387780
Device difficult to use 15.50 10.10 36 525840 10813 70391755
Dyspnoea at rest 15.48 10.10 95 525781 6724 70395844
Insulin C-peptide increased 15.39 10.10 10 525866 106 70402462
Transient ischaemic attack 15.39 10.10 448 525428 45496 70357072
Wrong dose 15.37 10.10 33 525843 1378 70401190
Hypoperfusion 15.35 10.10 47 525829 2446 70400122
Malnutrition 15.34 10.10 88 525788 20229 70382339
Genitourinary symptom 15.32 10.10 14 525862 254 70402314
Device malfunction 15.31 10.10 81 525795 19003 70383565
Genital swelling 15.27 10.10 15 525861 299 70402269
Phimosis 15.26 10.10 18 525858 445 70402123
Cryptococcosis 15.24 10.10 3 525873 3307 70399261
Paradoxical drug reaction 15.23 10.10 16 525860 6620 70395948
Cardiovascular insufficiency 15.21 10.10 50 525826 2703 70399865
Deep vein thrombosis postoperative 15.14 10.10 4 525872 3603 70398965
Injury 15.12 10.10 368 525508 64877 70337691
Drug eruption 15.10 10.10 204 525672 39292 70363276
Extrapyramidal disorder 15.07 10.10 91 525785 20659 70381909
Creatinine renal clearance 15.05 10.10 6 525870 19 70402549
Nodular rash 15.03 10.10 15 525861 305 70402263
Musculoskeletal pain 15.03 10.10 533 525343 89794 70312774
Altered state of consciousness 15.02 10.10 396 525480 39626 70362942
Periarthritis calcarea 14.99 10.10 9 525867 82 70402486
Ventricular enlargement 14.99 10.10 19 525857 507 70402061
Wrong technique in product usage process 14.97 10.10 391 525485 68307 70334261
Pneumonitis 14.93 10.10 300 525576 54297 70348271
Electrolyte imbalance 14.90 10.10 281 525595 26580 70375988
Blood cholesterol 14.88 10.10 20 525856 566 70402002
Staphylococcal bacteraemia 14.86 10.10 38 525838 11044 70391524
Mucosal dryness 14.81 10.10 55 525821 3161 70399407
Rash erythematous 14.80 10.10 282 525594 51436 70351132
Acute lymphocytic leukaemia recurrent 14.79 10.10 9 525867 4895 70397673
Neutrophilia 14.79 10.10 98 525778 7123 70395445
Varicella zoster virus infection 14.78 10.10 6 525870 4114 70398454
Blood sodium decreased 14.77 10.10 317 525559 30681 70371887
Haemorrhoids 14.76 10.10 120 525756 25468 70377100
Peripheral vascular disorder 14.69 10.10 102 525774 7530 70395038
Animal scratch 14.68 10.10 29 525847 1141 70401427
Cardiac failure chronic 14.64 10.10 128 525748 10141 70392427
Catheter site infection 14.61 10.10 14 525862 6046 70396522
Pruritus 14.61 10.10 2294 523582 343266 70059302
Melaena 14.60 10.10 533 525343 55822 70346746
Wound complication 14.57 10.10 67 525809 4242 70398326
Lymphoma 14.53 10.10 62 525814 15400 70387168
Haemoglobin decreased 14.53 10.10 1316 524560 203843 70198725
Hyperkinetic heart syndrome 14.50 10.10 10 525866 118 70402450
Cutaneous T-cell dyscrasia 14.40 10.10 8 525868 62 70402506
Tooth disorder 14.39 10.10 111 525765 23827 70378741
Cardiopulmonary failure 14.36 10.10 89 525787 6321 70396247
Anal incontinence 14.31 10.10 186 525690 16304 70386264
Pneumonia cytomegaloviral 14.29 10.10 8 525868 4553 70398015
Peripheral arterial occlusive disease 14.24 10.10 100 525776 7409 70395159
Pneumonia fungal 14.24 10.10 33 525843 9920 70392648
Miosis 14.22 10.10 55 525821 14046 70388522
Skin disorder 14.21 10.10 150 525726 30207 70372361
Coma uraemic 14.21 10.10 7 525869 41 70402527
Neuropathic ulcer 14.19 10.10 8 525868 64 70402504
Shock hypoglycaemic 14.18 10.10 13 525863 237 70402331
Peripheral circulatory failure 14.13 10.10 27 525849 1036 70401532
Eyelid bleeding 14.09 10.10 8 525868 65 70402503
Blood growth hormone increased 14.05 10.10 21 525855 657 70401911
Breast cancer female 14.03 10.10 36 525840 10450 70392118
Aplasia 13.99 10.10 20 525856 7231 70395337
Scleroderma 13.98 10.10 10 525866 4991 70397577
Bone pain 13.97 10.10 279 525597 50543 70352025
Prostatomegaly 13.96 10.10 54 525822 3165 70399403
Differential white blood cell count abnormal 13.95 10.10 38 525838 1850 70400718
Urine albumin/creatinine ratio increased 13.93 10.10 17 525859 436 70402132
Liver injury 13.92 10.10 217 525659 40818 70361750
Low density lipoprotein increased 13.92 10.10 105 525771 7960 70394608
Autoimmune pancreatitis 13.91 10.10 20 525856 604 70401964
Pyelonephritis acute 13.91 10.10 79 525797 5438 70397130
Osteopenia 13.89 10.10 70 525806 16627 70385941
Bronchostenosis 13.86 10.10 20 525856 606 70401962
Cerebral haematoma 13.85 10.10 98 525778 7280 70395288
Hepatic enzyme decreased 13.81 10.10 9 525867 96 70402472
Product solubility abnormal 13.80 10.10 24 525852 855 70401713
Coronary artery bypass 13.77 10.10 83 525793 5837 70396731
Pancreatitis necrotising 13.76 10.10 55 525821 3273 70399295
Pyelonephritis 13.72 10.10 201 525675 18088 70384480
Diabetic vascular disorder 13.65 10.10 9 525867 98 70402470
Spinal compression fracture 13.63 10.10 64 525812 15489 70387079
Jaundice hepatocellular 13.63 10.10 10 525866 131 70402437
Temperature regulation disorder 13.63 10.10 8 525868 4436 70398132
Drug dose titration not performed 13.62 10.10 22 525854 737 70401831
Pruritus genital 13.62 10.10 27 525849 1065 70401503
Bone disorder 13.61 10.10 75 525801 17415 70385153
Skin papilloma 13.61 10.10 12 525864 5394 70397174
Blood lactate dehydrogenase increased 13.58 10.10 181 525695 34946 70367622
Chorea 13.57 10.10 40 525836 2038 70400530
Pulmonary alveolar haemorrhage 13.57 10.10 36 525840 10333 70392235
Lower limb fracture 13.56 10.10 71 525805 16701 70385867
Genital rash 13.55 10.10 24 525852 868 70401700
Stenosis 13.54 10.10 40 525836 2041 70400527
Skin turgor decreased 13.52 10.10 21 525855 680 70401888
Hyponatraemic encephalopathy 13.52 10.10 14 525862 298 70402270
Intracranial pressure increased 13.50 10.10 21 525855 7335 70395233
Diabetic cheiroarthropathy 13.43 10.10 4 525872 3 70402565
Congenital hydrocephalus 13.43 10.10 7 525869 47 70402521
Clonus 13.41 10.10 16 525860 6252 70396316
Left atrial dilatation 13.36 10.10 49 525827 2800 70399768
Blood phosphorus increased 13.34 10.10 91 525785 6679 70395889
Bladder neoplasm 13.32 10.10 34 525842 1591 70400977
Orbital oedema 13.30 10.10 14 525862 304 70402264
Fluid intake reduced 13.29 10.10 79 525797 5528 70397040
Breast cancer 13.29 10.10 172 525704 33377 70369191
Retinal artery thrombosis 13.28 10.10 9 525867 103 70402465
Haematocrit decreased 13.25 10.10 323 525553 56935 70345633
Pneumonia bacterial 13.15 10.10 71 525805 16570 70385998
Optic neuritis 13.15 10.10 29 525847 8871 70393697
Autoimmune disorder 13.12 10.10 28 525848 8668 70393900
Skin haemorrhage 13.04 10.10 124 525752 10056 70392512
Fungaemia 13.02 10.10 7 525869 4075 70398493
Crush syndrome 13.02 10.10 11 525865 179 70402389
Paraesthesia 13.01 10.10 916 524960 144621 70257947
Urethral intrinsic sphincter deficiency 12.99 10.10 5 525871 14 70402554
Blood lactic acid abnormal 12.94 10.10 6 525870 30 70402538
Carbohydrate metabolism disorder 12.94 10.10 6 525870 30 70402538
Hereditary angioedema with normal C1 esterase inhibitor 12.90 10.10 4 525872 4 70402564
Venous aneurysm 12.90 10.10 4 525872 4 70402564
Intervertebral disc degeneration 12.90 10.10 56 525820 13844 70388724
Hypokinesia 12.85 10.10 191 525685 17241 70385327
Carcinoid tumour of the stomach 12.82 10.10 11 525865 183 70402385
Genital tract inflammation 12.79 10.10 6 525870 31 70402537
Jaundice 12.76 10.10 473 525403 49635 70352933
Pancreatic neuroendocrine tumour 12.76 10.10 20 525856 653 70401915
Septic shock 12.76 10.10 691 525185 111567 70291001
Endometriosis male 12.74 10.10 5 525871 15 70402553
Physical examination abnormal 12.73 10.10 13 525863 272 70402296
Chronic obstructive pulmonary disease 12.72 10.10 459 525417 77182 70325386
Premature labour 12.72 10.10 25 525851 7975 70394593
Oesophagitis 12.71 10.10 107 525769 22545 70380023
Cholangiocarcinoma 12.69 10.10 43 525833 2361 70400207
Food craving 12.65 10.10 32 525844 1489 70401079
Mycobacterial infection 12.65 10.10 5 525871 3483 70399085
Base excess 12.62 10.10 8 525868 81 70402487
Pancreatic failure 12.61 10.10 32 525844 1492 70401076
Product administration error 12.53 10.10 297 525579 29226 70373342
Secondary immunodeficiency 12.52 10.10 3 525873 2886 70399682
Gingival oedema 12.52 10.10 7 525869 55 70402513
Glycosylated haemoglobin 12.50 10.10 5 525871 16 70402552
pH urine decreased 12.50 10.10 5 525871 16 70402552
Alcoholic ketoacidosis 12.50 10.10 5 525871 16 70402552
Rheumatoid lung 12.47 10.10 5 525871 3454 70399114
Catheter site erythema 12.44 10.10 11 525865 4937 70397631
Red blood cells urine positive 12.41 10.10 10 525866 4699 70397869
Palmar-plantar erythrodysaesthesia syndrome 12.38 10.10 154 525722 30093 70372475
Fall 12.36 10.10 3581 522295 440515 69962053
Obliterative bronchiolitis 12.32 10.10 3 525873 2854 70399714
Pancreatic enzymes increased 12.32 10.10 28 525848 1216 70401352
Hypochromic anaemia 12.30 10.10 44 525832 2483 70400085
Lupus nephritis 12.30 10.10 3 525873 2851 70399717
Small intestinal obstruction 12.29 10.10 120 525756 24535 70378033
Hyperphagia 12.28 10.10 42 525834 2317 70400251
Bladder papilloma 12.28 10.10 5 525871 17 70402551
Cornea verticillata 12.26 10.10 9 525867 118 70402450
Gamma-glutamyltransferase abnormal 12.26 10.10 17 525859 496 70402072
Foetal death 12.24 10.10 17 525859 6222 70396346
Postoperative wound infection 12.24 10.10 43 525833 11295 70391273
Anal fissure 12.21 10.10 17 525859 6216 70396352
Pharyngitis streptococcal 12.21 10.10 33 525843 9415 70393153
Oral candidiasis 12.21 10.10 122 525754 24830 70377738
Hypoaesthesia eye 12.20 10.10 9 525867 119 70402449
Bacterial sepsis 12.07 10.10 24 525852 7623 70394945
Venous pressure jugular 12.06 10.10 5 525871 18 70402550
Respiratory rate increased 12.04 10.10 209 525667 19463 70383105
Blood ketone body present 12.02 10.10 7 525869 60 70402508
Bladder sphincter atony 12.01 10.10 9 525867 122 70402446
Vascular encephalopathy 12 10.10 18 525858 565 70402003
Prescription drug used without a prescription 11.97 10.10 49 525827 2948 70399620
Blood cholesterol decreased 11.97 10.10 33 525843 1618 70400950
Urticaria 11.97 10.10 1043 524833 162006 70240562
Glucose tolerance impaired 11.96 10.10 89 525787 6717 70395851
Oxygen saturation immeasurable 11.93 10.10 6 525870 37 70402531
Mitral valve thickening 11.93 10.10 15 525861 397 70402171
Clear cell renal cell carcinoma 11.92 10.10 41 525835 2269 70400299
Aortic stenosis 11.91 10.10 87 525789 6529 70396039
Respiratory depression 11.91 10.10 122 525754 24709 70377859
Epilepsy 11.87 10.10 209 525667 38575 70363993
Blood creatine increased 11.85 10.10 108 525768 8656 70393912
Catheter site haemorrhage 11.83 10.10 11 525865 4820 70397748
Plasmapheresis 11.82 10.10 19 525857 634 70401934
Diet failure 11.80 10.10 6 525870 38 70402530
Blood glucose 11.80 10.10 6 525870 38 70402530
Leukaemia recurrent 11.80 10.10 3 525873 2772 70399796
Glucose urine 11.80 10.10 6 525870 38 70402530
Lichenification 11.76 10.10 20 525856 700 70401868
Dyskinesia 11.74 10.10 224 525652 40850 70361718
Autonomic seizure 11.74 10.10 3 525873 0 70402568
Babinski reflex test 11.74 10.10 3 525873 0 70402568
Transitional cell carcinoma urethra 11.74 10.10 3 525873 0 70402568
Diabetic dyslipidaemia 11.74 10.10 3 525873 0 70402568
Infusion site pain 11.73 10.10 45 525831 11519 70391049
Intestinal ischaemia 11.73 10.10 139 525737 11925 70390643
Electroencephalogram abnormal 11.71 10.10 13 525863 5245 70397323
Mitral valve incompetence 11.69 10.10 270 525606 26458 70376110
Embolism venous 11.68 10.10 7 525869 3838 70398730
Lip swelling 11.66 10.10 333 525543 33721 70368847
Blood glucose normal 11.66 10.10 5 525871 20 70402548
Anaphylactic shock 11.64 10.10 170 525706 32320 70370248
Neck pain 11.63 10.10 391 525485 66266 70336302
Rhinitis allergic 11.62 10.10 33 525843 9262 70393306
Food allergy 11.61 10.10 29 525847 8495 70394073
Psychotic disorder 11.59 10.10 203 525673 37498 70365070
Cortisol increased 11.58 10.10 16 525860 465 70402103
Hepatosplenomegaly 11.58 10.10 15 525861 5655 70396913
Eructation 11.58 10.10 117 525759 9643 70392925
Central venous catheterisation 11.58 10.10 4 525872 3029 70399539
Epileptic encephalopathy 11.56 10.10 15 525861 410 70402158
Cellulitis of male external genital organ 11.55 10.10 6 525870 40 70402528
Red cell distribution width abnormal 11.50 10.10 11 525865 212 70402356
Enterococcal bacteraemia 11.49 10.10 3 525873 2723 70399845
Cognitive disorder 11.48 10.10 354 525522 60602 70341966
Drug abuser 11.48 10.10 16 525860 5848 70396720
Blood bicarbonate abnormal 11.48 10.10 9 525867 131 70402437
Genital infection female 11.37 10.10 7 525869 67 70402501
Blood triglycerides abnormal 11.36 10.10 15 525861 417 70402151
Therapeutic drug monitoring analysis not performed 11.33 10.10 31 525845 1513 70401055
Product blister packaging issue 11.33 10.10 10 525866 173 70402395
Acute lung injury 11.28 10.10 46 525830 2763 70399805
Dermatitis atopic 11.24 10.10 32 525844 8975 70393593
Hypertensive angiopathy 11.21 10.10 8 525868 100 70402468
Cardiac discomfort 11.20 10.10 26 525850 1145 70401423
Pulmonary hypertension 11.19 10.10 261 525615 46275 70356293
Wound infection 11.19 10.10 80 525796 17462 70385106
Psychogenic tremor 11.12 10.10 5 525871 23 70402545
Diabetic macroangiopathy 11.09 10.10 9 525867 138 70402430
Gastrointestinal toxicity 11.08 10.10 19 525857 6386 70396182
Inappropriate antidiuretic hormone secretion 11.08 10.10 238 525638 23038 70379530
Heart sounds 11.07 10.10 20 525856 735 70401833
Adrenomegaly 11.06 10.10 14 525862 373 70402195
Product complaint 11.05 10.10 139 525737 12092 70390476
Skin necrosis 11.03 10.10 73 525803 16218 70386350
Ototoxicity 11.02 10.10 4 525872 2937 70399631
Rebound effect 11 10.10 17 525859 5954 70396614
Clostridial infection 10.99 10.10 14 525862 5315 70397253
Photophobia 10.97 10.10 87 525789 18563 70384005
Bronchitis 10.97 10.10 735 525141 116508 70286060
Empty sella syndrome 10.95 10.10 7 525869 72 70402496
Thyroid cancer recurrent 10.95 10.10 5 525871 24 70402544
Electrocardiogram abnormal 10.94 10.10 161 525715 14503 70388065
Anaesthetic complication 10.92 10.10 3 525873 2633 70399935
Blood pressure inadequately controlled 10.92 10.10 75 525801 5517 70397051
Increased tendency to bruise 10.91 10.10 36 525840 9639 70392929
Acid base balance abnormal 10.91 10.10 13 525863 325 70402243
Blood albumin decreased 10.91 10.10 108 525768 22019 70380549
Ear congestion 10.89 10.10 40 525836 2287 70400281
Thirst decreased 10.89 10.10 12 525864 275 70402293
Chronic pigmented purpura 10.87 10.10 10 525866 183 70402385
Upper respiratory tract inflammation 10.86 10.10 8 525868 3934 70398634
Intentional self-injury 10.86 10.10 167 525709 31483 70371085
Blood urea abnormal 10.82 10.10 27 525849 1246 70401322
Disease recurrence 10.77 10.10 205 525671 37398 70365170
Lipids abnormal 10.76 10.10 17 525859 559 70402009
Haemorrhage urinary tract 10.72 10.10 40 525836 2305 70400263
Hydrops foetalis 10.70 10.10 11 525865 232 70402336
Cardiac failure congestive 10.66 10.10 1154 524722 134303 70268265
Myalgia 10.66 10.10 1411 524465 166481 70236087
Arteriosclerosis 10.63 10.10 178 525698 16460 70386108
Bladder transitional cell carcinoma stage III 10.63 10.10 5 525871 26 70402542
Blood osmolarity increased 10.62 10.10 17 525859 565 70402003
Fistula 10.62 10.10 43 525833 10838 70391730
IIIrd nerve paralysis 10.58 10.10 25 525851 1114 70401454
Muscle necrosis 10.58 10.10 28 525848 1340 70401228
Systemic infection 10.56 10.10 85 525791 6572 70395996
Prolonged expiration 10.56 10.10 23 525853 970 70401598
Renal cyst 10.54 10.10 148 525728 13197 70389371
Gingival hypertrophy 10.50 10.10 46 525830 2852 70399716
Lactate pyruvate ratio increased 10.48 10.10 7 525869 78 70402490
Melanocytic naevus 10.47 10.10 10 525866 4326 70398242
Drug level decreased 10.46 10.10 53 525823 12571 70389997
Soft tissue disorder 10.45 10.10 6 525870 3368 70399200
X-ray abnormal 10.45 10.10 3 525873 2557 70400011
Disseminated tuberculosis 10.44 10.10 9 525867 4091 70398477
Viral mutation identified 10.44 10.10 7 525869 3615 70398953
Subdural hygroma 10.43 10.10 15 525861 453 70402115
Meningitis 10.42 10.10 32 525844 8761 70393807
Inferior vena cava dilatation 10.42 10.10 20 525856 770 70401798
Blood lactate dehydrogenase decreased 10.42 10.10 12 525864 289 70402279
Vascular device infection 10.41 10.10 28 525848 8002 70394566
Choluria 10.37 10.10 13 525863 343 70402225
Foreign body in reproductive tract 10.36 10.10 15 525861 456 70402112
Disorientation 10.33 10.10 527 525349 57396 70345172
Infusion site extravasation 10.33 10.10 28 525848 7980 70394588
Cushingoid 10.32 10.10 30 525846 8358 70394210
Gallbladder oedema 10.29 10.10 12 525864 293 70402275
Skin induration 10.26 10.10 10 525866 4285 70398283
Lichen sclerosus 10.24 10.10 22 525854 919 70401649
Stem cell transplant 10.24 10.10 7 525869 3578 70398990
Blood urine present 10.24 10.10 201 525675 19152 70383416
Tumour compression 10.23 10.10 9 525867 155 70402413
Systemic mycosis 10.21 10.10 3 525873 2519 70400049
Leukocyturia 10.21 10.10 31 525845 1606 70400962
Intraductal papillary-mucinous carcinoma of pancreas 10.19 10.10 4 525872 12 70402556
Locomotive syndrome 10.19 10.10 4 525872 12 70402556
Non-high-density lipoprotein cholesterol decreased 10.19 10.10 4 525872 12 70402556
Albumin globulin ratio abnormal 10.19 10.10 4 525872 12 70402556
Diabetic eye disease 10.18 10.10 9 525867 156 70402412
Illness 10.16 10.10 170 525706 31621 70370947
Acanthosis 10.14 10.10 15 525861 465 70402103
Myoclonus 10.12 10.10 136 525740 26219 70376349
Bronchospasm 10.12 10.10 114 525762 22678 70379890
Suicidal behaviour 10.10 10.10 5 525871 3051 70399517
Echocardiogram abnormal 10.10 10.10 35 525841 1944 70400624
Muscle twitching 10.10 10.10 96 525780 19731 70382837

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD26 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0002471 Biguanides
FDA EPC N0000175565 Biguanide
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Polycystic ovary syndrome off-label use 237055002 DOID:11612
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe Hypoxemia contraindication
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Autonomic Insufficiency contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 6699871 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7125873 July 26, 2022 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Feb. 22, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Feb. 22, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL Feb. 22, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Feb. 22, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Feb. 22, 2022 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL May 2, 2022 NEW PRODUCT
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL July 3, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Aug. 12, 2022 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Oct. 18, 2022 TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Dec. 19, 2022 NEW CHEMICAL ENTITY
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MERCK SHARP DOHME N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
D00944 KEGG_DRUG
1115-70-4 SECONDARY_CAS_RN
4020898 VANDF
4023979 VANDF
C0025598 UMLSCUI
CHEBI:6801 CHEBI
MF8 PDB_CHEM_ID
CHEMBL1431 ChEMBL_ID
4091 PUBCHEM_CID
DB00331 DRUGBANK_ID
CHEMBL1703 ChEMBL_ID
D008687 MESH_DESCRIPTOR_UI
965 INN_ID
4779 IUPHAR_LIGAND_ID
9100L32L2N UNII
151827 RXNORM
41717 MMSL
5063 MMSL
592 MMSL
d03807 MMSL
003483 NDDF
004534 NDDF
109081006 SNOMEDCT_US
109083009 SNOMEDCT_US
372567009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2751 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2751 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2752 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2752 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2753 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glyburide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0228-2753 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6125 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6135 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
KOMBIGLYZEXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6145 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections